Stenting Esophageal Disease by Heel, N.C.M. (Nicoline) van


Stenting Esophageal Disease
Nicoline C.M. van Heel
© N.C.M. van Heel, The Netherlands 2011. All rights reserved. No part of this thesis may 
be reproduced or transmitted in any form or by any means, without prior permission 
of the author.
Cover: Elly Hemmes 
Layout and printing: Optima Grafische Communicatie, Rotterdam, The Netherlands 
The work presented in this thesis was conducted at the Department of Gastroenterology 
and Hepatology, Erasmus MC University Medical Center Rotterdam, The Netherlands.
Financial support for printing this thesis was kindly given by the Department of 
Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, 
Nederlandse Vereniging voor Gastroenterologie, Abbott Immunology B.V., Zambon 
Nederland B.V., Roche Nederland B.V., Olympus Nederland B.V., UCB Pharma B.V., 
Ferring B.V., Cook Medical, MSD, Pentax Nederland B.V., Abbott Products B.V., Boston 
Scientific Nederland B.V., Dr. Falk Pharma Benelux B.V., J.E. Jurriaanse Stichting, Vifor 
Pharma Nederland B.V.
Stenting Esophageal Disease
Stenttherapie bij slokdarmaandoeningen
PROEFSCHRIFT
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof. dr. H.G. Schmidt
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
donderdag 22 december 2011 om 11:30 uur
door
Nicoline Carolina Maria van Heel
geboren te Leusden
PROMOTIECOMMISSIE
Promotor: Prof. dr. E.J. Kuipers
Overige leden:  Prof. dr. H.W. Tilanus
  Prof. dr. M.J. Bruno
  Prof. dr. J.F.W.M. Bartelsman
CONTENTS 
Chapter 1 Introduction and outline of the thesis 7
Chapter 2 Are we making progress in diagnosing and preventing  
gastrointestinal cancers?
19
Chapter 3 Esophageal stents for the palliation of malignant dysphagia and 
fistula recurrence after esophagectomy
33
Chapter 4 Esophageal stents for the relief of malignant dysphagia due to 
extrinsic compression
47
Chapter 5 Comparison of two expandable stents for malignant esophageal 
disease: a randomized controlled trial 
61
Chapter 6 Endoscopic removal of self-expandable stents from the esophagus 77
Chapter 7 Short-term esophageal stenting in the management of benign 
perforations
93
Chapter 8 Partially- versus fully-covered expandable metal endoprosthesis for 
benign esophageal disease: a randomized controlled trial
107
Chapter 9 General discussion and future perspectives 123
Summary 137
Summary in Dutch 143
List of publications 149
PhD Portfolio 153
Acknowledgements 159
Curriculum Vitae 165

Chapter 1
Introduction and outline of the thesis

9Introduction and outline of the thesis
Chapter 1
INTRODuCTION
In 1885, Charles Symonds placed the first rigid endoprosthesis across a malignant esopha-
geal stricture.1 With the introduction of the fiberoptic endoscope and the development of 
the rigid Celestin tube nearly one century later, the revolution was initiated.2 Over the past 2 
decades, esophageal stents have drastically improved. Prior to 1990, stents were made from 
rigid polyvinyl plastic or rubber. These prostheses were able to restore luminal patency, how-
ever placement was difficult and bleeding, pain, and perforations frequently occurred.3 In 
the early nineties, rigid endoprostheses were replaced by uncovered self-expandable metal 
stents (SEMS). SEMS placement appeared to be less invasive, provided wider lumen, and was 
associated with fewer complications. However, new problems soon appeared.4-5 Through the 
uncovered mesh tumor ingrowth frequently occurred, leading to recurrent dysphagia shortly 
after placement. To impede tissue ingrowth, SEMS were modified with a plastic or silicone 
layer in the middle of the endoprosthesis.6-8 These partially-covered SEMS (PCSEMS) were not 
only able to re-open a blocked esophagus, but also sealed malignant esophagorespiratory 
fistulae. In 2001, removable fully covered metal stents (FCSEMS) and plastic stents (SEPS) 
were introduced. The ability to remove these stents after deployment has opened up new 
applications, such as the insertion of a stents as a temporary device in patients with benign 
esophageal fistulae or stenosis and to bridge chemo- and radiotherapy in patients with 
malignant esophageal disease.9-10 Initial results were suboptimal as well. Fully-covered ex-
pandable stents were associated with a higher migration rate. SEMS are generally preloaded 
in a thin delivery catheter, yet FCSEPS require being loaded onto the significantly larger and 
stiffer delivery device.11-12 Various stent designs are shown in Figure 1.
Figure 1. Current generation covered self-expandable stents. 
Left to right: Ultraflex stent, Evolution stent, Hanarostent, Polyflex stent.
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Esophageal stents in malignant disease
Esophageal cancer represents one of the most lethal malignancies worldwide. The incidence 
of esophageal carcinoma is rising rapidly in developed countries because of an increase in 
the frequency of adenocarcinoma, at a rate exceeding that of any other neoplasm.13 The most 
common symptom of esophageal cancer at the time of presentation is dysphagia. Malignant 
dysphagia is defined as difficulty in swallowing due to stenosis of the esophageal lumen, and 
correlates with more than 50% occlusion of the esophageal lumen. Sialorrhea is a devastat-
ing symptom associated with esophageal obstruction. The rapid accumulation of saliva and 
regurgitation is a common complaint that causes daytime misery with frequent spitting, as 
well as insomnia and the increased risk of aspiration pneumonia. The majority of patients 
have incurable disease at the time of diagnosis because of distant metastases, locally ad-
vanced disease or their poor medical condition.14-15 The palliative management of patients 
with a malignant esophageal obstruction is a clinical challenge. General supportive care, 
relief of pain, and restoration of adequate nutritional status, are all essential components 
of optimal therapy. The gastroenterologist has to balance the benefits of restoring luminal 
patency by SEMS on patients’ quality of life in the context of a short life-expectancy, with the 
risk of procedural complications and the burden of reinterventions. Although chemotherapy 
and radiotherapy are sometimes beneficial, they may require several weeks to improve dys-
phagia.16 Generally, a more rapid relief of dysphagia is desired. Currently, SEMS placement is 
the most widely used palliative treatment in patients with malignant dysphagia.17 Adequate 
placement immediately restores luminal patency and thereby improves oral intake and qual-
ity of life.18-20
Esophageal stents in benign disease
Benign esophageal leaks comprise asset of life-threatening conditions that require early rec-
ognition and aggressive management. Lesions include iatrogenic perforations, anastomotic 
leaks after surgery, and transmural tears due to Boerhaave’s syndrome.21-23 The mortality rate 
of esophageal perforation is reported to be as high as a 100% when left untreated, as a result 
of mediastinitis, sepsis and multiple organ failure.24 A small subset of patients can be treated 
conservatively with nil per mouth, antibiotics and drainage of pleural empyemas. Surgical 
treatment options include esophageal repair and esophagectomy; the mortality rate after 
surgery is in the range of 12 – 50%.25-28 
 
A benign esophageal stricture is frequently encountered as a complexity in endoscopic 
practice.29 They can result from peptic injury, radiation injury, caustic injury and anastomotic 
lesions. For centuries, the gold standard for esophageal strictures has been dilation therapy. 
11
Introduction and outline of the thesis
Chapter 1
While initial dilation typically results in symptomatic relief, recurrence of the stricture is a 
common phenomenon. 
Over the past few years, stents have been used as a temporary device to firmly seal the lesion 
or to restore luminal patency in patients with benign esophageal disease. Thus far, this ap-
plication is limited because of serious concerns regarding the long-term complications and 
hitches relating to stent extraction.30-31
AIM OF THE THESIS
The aim of the thesis is to explore new applications and designs to improve benefits, and 
to overcome limitations of self-expandable stents in patients with malignant and benign 
esophageal disease.
OuTlINE OF THE THESIS
By measures of mortality and morbidity gastrointestinal (GI) cancers are leading the field 
of oncology. Between one fifth and one quarter of all human cancers arise in the digestive 
system. Many patients with gastrointestinal cancer present with incurable disease. As locally 
advanced cancer often goes with distant metastases, treatment options are mostly limited 
to systemic treatment or local palliation only. Despite the many enhancements in cytotoxic 
therapy and novel biologic agents, overall progress in the outcome of metastatic disease is 
poor. In chapter 2 we focus on recent developments in cancer prevention, detection and the 
approach to early cancer.
Surgical resection is the only curative treatment option for invasive esophageal cancer. 
However, despite careful staging and advances in adjuvant therapy and surgical techniques, 
5-year survival rates rarely exceed 40%.32-33 Many patients present with locoregional recur-
rence and distant metastasis die within 2 years after curative esophagectomy.34 Treatment 
of patients with local disease recurrence aims at relieving dysphagia. The clinical efficacy of 
SEMS in patients with dysphagia or fistula caused by recurrent cancer after esophagectomy 
is not well documented. We therefore assessed in chapter 3 the safety and efficacy of SEMS 
insertion in a cohort of patients with this condition.
Malignant extrinsic compression can be caused by local recurrence of cancer after esopha-
gectomy, pulmonary cancer, mediastinal cancer, or metastatic disease.35-36 Most patients with 
dysphagia due to malignant extrinsic compression are incurable and have a life expectancy 
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of less than 6 months after initial symptoms. Treatment of patients with non-resectable meta-
static disease is palliative; by relieving dysphagia, nutritional intake can be maintained and 
quality of life improved.20 The vast majority of previous studies tend to combine intrinsic and 
extrinsic malignancies. However dysphagia due to extrinsic compression differs essentially 
from dysphagia due to primary esophageal cancer. It generally presents late in the disease, 
it causes displacement of the lumen rather than structuring and is associated with a broad 
set of symptoms and a brief life-expectancy. For this reason, in chapter 4 we investigated the 
safety and efficacy of SEMS placement in patients with extrinsic compression.
A wide variety of expandable esophageal endoprostheses have been developed, aiming to 
improve the therapeutic outcome and to reduce the need for endoscopic reintervention 
during the course of the disease. Unfortunately, the number of reinterventions remain sig-
nificant.37-39 Currently, the Ultraflex® stent is worldwide most frequently used. The Evolution® 
stent has recently been introduced to the market. This stent differs considerably from the 
current available SEMS: in delivery system, size, shape, flares, and covering. In chapter 5, we 
aimed to assess whether such new design is superior to the conventional Ultraflex stent for 
the palliative management of patients with malignant dysphagia or esophageal fistulae.
Covered self-expandable metal stents (SEMS) were introduced as a permanent device for the 
palliative therapy of esophageal carcinoma. The newest generation SEMS with a covering 
membrane prevents tissue ingrowth and allows sealing of a fistula. In addition, the cover also 
facilitates SEMS removal by preventing stent embedment.40 Currently, SEMS are increasingly 
used as a temporary device in patients with benign esophageal defects and stenosis, or to 
bridge chemo-radiotherapy in patients with malignant esophageal disease.41-47 However, 
severe complications during SEMS removal have been reported but most series published to 
date are small.30-31, 43, 46, 48-49 Hence, this prompted us to evaluate in chapter 6 our experience 
with endoscopic SEMS removal in the largest cohort of patients to date with benign and ma-
lignant esophageal disease and to identify factors associated with SEMS removal outcome.
Over the last few years, good results for the management of benign esophageal perforations 
have been reported by temporary deployment of a covered self-expandable stent to firmly 
seal the lesion.9, 41-42, 48 Although stent placement is a minimal invasive procedure,50-52 stent 
therapy is associated with severe complications including hemorrhage, incomplete sealing, 
perforation, and stent migration.37-38 Even though some of the newer stents are labeled as 
being removable, extraction can be complex due to embedding of the endoprostheses into 
the mucosal wall.48 The optimal duration of stent therapy has not been established.48, 53 The 
aim of chapter 7 was to evaluate the outcome of temporary esophageal stenting in the 
management of benign perforations.
13
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Major drawbacks of the current available stents are the re-occurrence of dysphagia and 
leakage caused by SEMS migration. Features in the design of the stent that help to prevent 
migration, including the type of covering, also hamper stent removal once they are in posi-
tion. Because to date no randomized studies have been published comparing fully-covered 
SEMS  and partially-covered SEMS, in chapter 8 we compared their efficacy in patients with 
benign esophageal disease in a randomized controlled study design.
Chapter 1
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INTRODuCTION
By measures of mortality and morbidity gastrointestinal (GI) cancers are leading the field 
of oncology. Between one fifth and one quarter of all human cancers arise in the digestive 
system. Many patients with cancer of the digestive system present with incurable disease. As 
locally advanced cancer often goes with distant metastases, treatment options are mostly 
limited to systemic treatment or local palliation only. Despite the many enhancements in 
cytotoxic therapy and novel biologic agents, overall progress in the outcome of metastatic 
disease is poor.1-2  
The fact that most GI cancers are for long preceded by recognizable, treatable precursor 
lesions has posed great challenges. Primary prevention strategies seek to prevent the forma-
tion of cancer in an otherwise healthy population. Secondary prevention activities are aimed 
at early disease detection, thereby  increasing the opportunities for interventions to prevent 
progression of the disease. Advanced diagnostic and therapeutic tools have been developed 
to detect and treat cancerous lesions at the earliest stage. With these tools and increased 
awareness of their impact, early treatment and prevention have become a major task for 
the modern gastroenterologist. In this review we focus on recent developments in cancer 
prevention, detection and the approach to early  cancer. 
RISk FACTORS AND PRECuRSOR lESIONS 
Pathogenesis of most GI cancers follows a sequential, multistep process with well-defined 
biological stages, developing from low-grade dysplasia to high-grade dysplasia, and finally to 
invasive carcinoma.3-4 This is a complex process in which various acquired and inborn genetic 
factors are involved. Chronic injury and inflammation play a critical role in the majority of 
GI cancers. The inflammatory process induces oxidative stress, and initiates replacement of 
injured and damaged cells by a continual regenerative process with risk of DNA damage and 
uncontrolled cell proliferation.5
There are numerous well-recognized conditions in the GI tract that predispose to cancer. 
Such premalignant conditions include Barrett’s metaplasia and achalasia of the esophagus, 
atrophy and metaplasia of the stomach, chronic inflammation of the biliary tract and pan-
creas, chronic inflammatory bowel disease, and colonic polyp syndromes. 
The use of biomarkers for risk identification may have infinite potential. There have been 
several attempts to identify markers of tumor DNA shed from tumors into stool. Although 
there is evidence that this noninvasive approach is useful, there are still important barriers in 
Chapter 2
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terms of sensitivity, specificity, and cost. At present, a panel of DNA markers can identify over 
50% of patients with colorectal cancer (CRC) and many patients with advanced adenomas.6 
Risk scores based on simple clinical, histological, and serological parameters can already 
serve as a practical tool to select patients for surveillance endoscopy. Intragastric extent of 
intestinal metaplasia is an example of an indicator for gastric cancer risk that can be assessed 
by a score based on individual risk factors.7
SCREENINg AND SuRvEIllANCE
The key purpose of screening and surveillance protocols is the detection of presymptomatic 
curable disease. It is of crucial importance for the efficacy of screening and surveillance pro-
grams that the natural history of the target disease consists of a sequential process with well-
defined biological stages, and that in this sequence a so called critical point along its natural 
history is identified. This critical point is best described as the point during the multistep 
process before which treatment is either more effective than afterwards, or equally effective 
but easier to apply.8 This critical point should be noticeable by a reliable and efficient  screen-
ing technique. Furthermore, the critical point has to lie between the earliest possible time of 
diagnosis and the usual time of clinical diagnosis. 
Some GI cancers in various risk areas do not satisfy the basic conditions, whereas others are 
unbiased candidates for effective large-scale screening and surveillance programs. For those 
candidates, such as Barrett’s, gastric premalignant lesions and colon adenomas, the effect 
of surveillance on the incidence of advanced cancer and mortality has to be proven before 
launching large-scale stratified screening and surveillance programs.9-12 The availability of 
mass screening programs in high-risk countries for gastric cancer has substantially decreased 
mortality.13 In contrast, in North America and Europe where such programs are lacking and 
few gastric cancers are detected at an early stage, cancer survival is significantly worse.14 For 
CRC in the Western world a trend towards such reduction is documented.15 For esophageal 
cancer, even in the setting of Barrett’s metaplasia, survival benefit has not convincingly been 
shown.
CHEMOPREvENTION
To reduce the incidence and outcome of GI cancer, chemoprevention strategies represent 
an alternative approach to screening and surveillance programs.16 This can be achieved for 
various tumors with a variety of methods, some of which required maintenance treatment 
23
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whereas others only require a single short-term intervention. One of the most remarkable 
examples in the latter group is chemoprevention of gastric cancer and gastric mucosa-
associated lymphoid tissue (MALT) lymphoma by antimicrobial therapy against Helicobacter 
pylori. H. pylori eradication leads to a rapid resolution of chronic active gastritis. This can 
to some extent be accompanied by a regression of atrophic gastritis, but, it seems, not of 
intestinal metaplasia. Several large randomized prospective studies have reported that H. 
pylori eradication thus reduces the incidence of gastric cancer. A recent meta-analysis of 
seven large studies reported that H. pylori eradication was in the first years thereafter associ-
ated with a 35% reduction in gastric cancer incidence.17 All of these studies were performed 
in areas with a high gastric cancer incidence, in particular in Asia. It thus remains unclear 
whether these results can be translated to other populations. We do however know that the 
development of gastric cancer after H. pylori eradication is not only an early phenomenon, 
but can still occur more than a decade after eradication.18 Further studies, in particular in 
Western populations, are badly needed. 
With respect to long-term chemoprevention, the group of drugs that has generated the most 
attention is the nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit the cyclooxygen-
ase enzymes. Well-conducted animal studies, as well as epidemiologic studies in humans, 
have shown that the regular use of NSAIDs is clearly associated with a reduction of GI cancer 
risk.19-22 The protective effect is dose-dependent and is directly related to the duration of 
exposure.23-24 However, traditional NSAIDs are known to cause renal toxicity as well as injury 
to the mucosa of the digestive system, resulting in renal failure, bleeding, ulceration and 
stricturing of the GI tract. The cyclooxigenase-2 (COX-2) selective inhibitors were considered 
in the search for an alternative chemopreventive agent with fewer side effects. Recent large-
scale studies have shown an increased risk of cardiovascular events, raising serious concerns 
on the safety of COX-2 inhibitors in chemoprevention strategies.25-26 Furthermore, a subset 
of GI cancers (20%) has low expression of COX-2, indicating that these tumors could be less 
responsive to COX-2 prevention. 
A second category of drugs that are widely investigated for chemoprevention of upper GI 
cancers, both alone and in combination with NSAIDs, are proton-pump inhibitors. These 
studies focus in particular on the effect of proton-pump inhibitor maintenance therapy and 
the risk of development of esophageal adenocarcinoma in patients with Barrett’s esophagus. 
Several cohort studies have shown that proton-pump inhibitor therapy cannot fully prevent 
the development of Barrett’s esophagus,27 although it is unknown whether they slow the 
rate of development of Barrett’s metaplasia. Furthermore, there are several cohort studies 
which report that proton-pump inhibitor therapy decreases the progression of pre-existent 
Barrett’s mucosa to dysplasia and cancer, yet this observation is not consistent throughout 
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the complete literature.28 This implies that much further research is needed in the coming 
years on this very important topic.  
A third category under investigation as chemopreventive agents for GI cancer are statins. In 
humans simvastatin and pravastatin are associated with a reduced CRC rate in patients with 
coronary artery disease, with a relative risk reduction of 47% after 5 years.29 Although statins 
have been shown to be associated with an acceptable adverse effect profile in patients with 
hypercholesterolemia, their longterm toxicity in patients without hyperlipidemia has yet to 
be assessed. 
Estrogen may prevent the CRC by decreasing the production of secondary bile acids, by 
decreasing production of insulin-like growth factor 1, or by exerting a direct effect on the 
epithelium. Estrogen in combination with progesterone can induce a 37% reduction in CRC 
incidence in women. However, such hormonal treatment is associated with increased inci-
dences of cardiovascular events, breast cancer, thromboembolic events and stroke.30 
Mesalamine has been studied mostly in the setting of prevention of CRC in patients with 
inflammatory bowel disease. While some studies show an impressive protective effect, others 
have failed to confirm these findings.31-32 
Altogether, this indicates that the potential chemoprevention strategies have to be re-
evaluated and effective chemoprevention remains at best at the horizon.
IMAgINg EARly CANCER
For all GI cancers, the most significant prognostic factor for survival is the stage at diagno-
sis.33-34 In the majority of patients with symptoms, the cancer has invaded into the muscularis 
propria or beyond. Early cancer is defined as tumor limited to the mucosa or extending into 
the submucosa but not invading the outer muscular wall. If diagnosed in an early stage, GI 
cancer is curable and has an excellent prognosis (Table 1). Since asymptomatic patients are 
TABLE 1. Five-year relative survival rate by stage.
TNM classification Esophageal cancer Gastric cancer Colorectal cancer
 0  >95%  >90%  >95%
I 50-80% 50-80% 90-95%
II 10-40% 30-50% 70-85%
III 10-15% 10-20% 35-66%
IV <5% <5% <5%
TNM, Tumor-Node-Metastases
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not routinely exposed to early cancer diagnosis, these early cancers are either picked up 
through dedicated screening and surveillance, or during medical work-up for other reasons.35
Despite the many enhancements in diagnostic radiology and promising developments in the 
field of immunochemical detection, endoscopy with histological biopsy continues to play a 
leading role in the diagnosis of early GI cancer.36  
Endoscopic detection of cancer in its early stage can be difficult as most early neoplastic 
lesions have a normal macroscopic appearance. Precursor abnormalities and early lesions are 
frequently overlooked, even by the experienced endoscopist.  Random biopsy protocols such 
as in Barrett’s esophagus also frequently miss dysplastic or cancerous areas.37 Novel enhance-
ments in endoscopic imaging techniques facilitate visualization and increase detection of 
early neoplastic lesions to a great extent. The leading enhancement techniques are high-
resolution imaging, magnification endoscopy, spectral filtering techniques, and autofluores-
cence endoscopy.38-42 Although still in their infancy, these imaging techniques have already 
started to take the place of  chromoendoscopy and meticulous random biopsy protocols.
MANAgEMENT OF PRECuRSOR lESIONS AND EARly CANCER TREATMENT
Surgery is still considered the standard treatment for patients with GI cancer. For many 
years however, endoscopic therapy has become available for certain precursor lesions and 
early cancer, with significant benefits and excellent outcome. Colonoscopic snare resection 
of stalked polyps has been employed successfully since the early 1970s.43 Subsequently, 
various other techniques have been developed to routinely remove precursor lesions from 
the GI tract at endoscopy, including hot biopsy removal, cold snaring, piecemeal resection, 
and argon plasma coagulation. While protruded lesions up to 2 cm in the colorectum can be 
easily excised by these techniques, other nonprotruded lesion types and superficial cancers 
in the intestine, stomach and esophagus can be removed with more advanced endoscopic 
resection techniques. Although standard polypectomy can be considered a form of endo-
scopic resection, this terminology generally applies for ‘deeper’ types of resection, extend-
ing into the submucosa. The most widely applied techniques for endoscopic resection are 
endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD).44-47  
The feasibility, safety, and results of endoscopic resection predominantly depend on operator 
experience.48 Recent long-term studies have shown that prognosis of complete en-bloc EMR 
for differentiated, nonulcerated mucosal early gastric cancers under 20 mm is comparable 
to surgical treatment with 10-year survival rates as high as 99%.49 Other studies have shown 
the cost efficacy of such approach.50 Although some advocate endoscopic treatment of 
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smaller undifferentiated cancers and early cancers invading the submucosa,51 generally only 
high-grade dysplasias and well differentiated nonulcerated GI cancers that are limited to the 
mucosa are candidates for endoscopic resection, as these lesions have a well-determined low 
risk for lymph node metastasis.52-55 En-bloc resection is preferred over piecemeal resection, 
irrespective of the resection technique employed.56  
The risk of complications using these endoscopic minimally invasive resection techniques 
(i.e. bleeding, perforation, stenosis), are significant, but low in comparison with the risks of 
a surgical procedure.57 En-bloc resection techniques for larger lesions carry a considerably 
higher complication rate than EMR techniques, even in the hands of experts.48 
ARE wE MAkINg PROgRESS?
GI cancer is amongst the most common cancers and a major cause of caner-related death 
around the world. The incidence, diagnostic techniques, therapeutic options have under-
gone major changes over the last six decades, but the prognosis generally remains poor, 
especially in advanced stages and in spite of aggressive adjuvant therapy and advances in 
surgical resection techniques. At the same time the understanding of carcinogenesis has 
advanced considerably leading to a marked shift towards risk stratification, prevention, early 
detection, and early treatment. 
The results of primary prevention strategies are lagging behind the initial expectations, yet 
the availability of mass screening programs in high-risk populations has already substantially 
decreased mortality in certain cancers.58-60 It is important to note that benefit should exceed 
the burden of large-scale surveillance programs and such benefit remains  controversial as 
long as documented reduction on cancer mortality is lacking.61 
The reason for the increased detection of early cancer is not only the success of the mass 
screening programs but also the awareness of physicians towards recognizing individual 
risks, and the attitude towards detecting early cancer in asymptomatic subjects. It may be 
that the paradigm shift to recognition of precancerous lesions in the GI tract is the corner-
stone of progress made in preventing GI cancer and early interventions. GI cancers, which 
were previously considered fatal, may now be managed at an early and curable stage. 
In such approach, successful prevention of GI cancer relies upon the identification of risk 
factors and risk groups, availability of early detection and treatment protocols, expert centers 
for applying these measures to patients, and continuous evaluation of and development of 
procedures applied. The goal of screening and surveillance is to diagnose precursor lesions 
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and early stage cancer and to intervene at a critical point in order to prevent progression to 
advanced cancer or preclude mutilating therapy. Studies have shown a survival benefit if the 
cancers are detected by endoscopic screening rather than when presenting with symptoms.
Surgery has long been the standard treatment also for patients with early GI cancer; however 
there is a shift toward alternative less-invasive organ-sparing therapy. Endoscopic tools for the 
complete removal of early cancerous lesions have been developed with significant benefits 
and excellent outcome. These endoscopic techniques carry considerably lower morbidity, 
mortality, and long-term side effects as compared with surgical intervention. These benefits 
outweigh even the higher risk of local cancer recurrence. Some of these techniques such as 
polypectomy for the prevention of colon cancer have been employed for decades and have 
been proven safe in the hands of many. Given the risks and the lack of long-term outcome 
data for some of the newer and more aggressive endoscopic techniques, these should be 
restricted to experienced endoscopists in expert centers because it requires high levels of 
endoscopic skill and experience. 
FuTuRE DIRECTIONS
In recent years important advances have been achieved in the adjuvant treatment of advanced 
cancers, where small yet firm survival benefits were demonstrated for perioperative chemo-
therapy and postoperative chemoradiotherapy. Even though patient prognosis for advanced 
disease remains very poor with median survival times rarely approaching 1 year, efforts to 
improve outcome of multimodality treatment for advanced disease should continue. Yet, one 
of the greatest challenges now facing this field is the identification of patients at risk and as-
sessing individuals for the presence of precursor lesions with the aim of targeting only those 
with a survival benefit with the psychological and physical burden of regular surveillance. The 
use of biomarkers and simple clinical scoring systems for risk identification both have a great 
potential and hence provide an opportunity for less-invasive, more-effective screening and 
surveillance. Attempts are being made to validate these approaches in routine clinical practice. 
Detection of the precancerous lesions in a high risk population is an essential clinical goal. 
New optical developments are rapidly in progress. Ongoing research, teaching and training 
are essential to optimize detection skills. Endoscopy will continue to play a leading role in the 
treatment of patients with an identified precursor lesion or mucosal cancer, but minimally in-
vasive surgical techniques can also be developed to be used as an alternative in cases referred 
for maximally invasive surgical resection at present. Expectations for future technology are 
high; however, to establish the value of various advanced diagnostic and therapeutic tools 
in preventing GI cancer, long-term outcomes of randomized controlled trials are required.
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AbSTRACT
Background: Despite advances in staging methods, surgical techniques, and adjuvant treat-
ment, recurrent cancer after esophagectomy is a major cause of morbidity and mortality.
Objective: Our purpose was to investigate the safety and efficacy of a self-expandable metal 
stent (SEMS) in patients with dysphagia or fistula caused by recurrent cancer after esopha-
gectomy.
Design: Prospective, observational study with standardized treatment and follow-up.
Setting: Single university center.
Patients: In 81 patients with recurrent cancer after previous surgical esophagectomy, 100 
esophageal SEMSs were inserted for dysphagia (n = 66) or fistula formation (n = 15).
Interventions: Stent placement.
Main Outcome Measurements: Technical and functional outcome, complications, and survival.
Results: The SEMSs restored luminal patency in 65 (98%) of 66 patients and sealed malignant 
fistulae in 14 (93%) of 15 patients. Stent dysfunction occurred in 24 (30%) of 81 patients. They 
all were successfully managed by subsequent endoscopic intervention. After stent place-
ment, a total of 16 complications were observed. Major complications occurred in 9 (11%) 
of 81 patients, mild complications occurred in 7 (9%). The overall 30-day mortality rate after 
stent insertion was 25%. Progression of the disease resulted in death after a median interval 
of 70 days (range 1 day to 91 months).
Limitations: Nonrandomized design.
Conclusions: SEMS placement in recurrent esophageal cancer after surgical resection offers 
adequate palliation by relieving dysphagia and sealing off esophageal respiratory fistulae. 
Therefore, in these patients who have a relatively short life expectancy, SEMS placement 
should be considered the treatment of choice.
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INTRODuCTION
Surgical resection is the only curative treatment option for invasive esophageal cancer. 
However, despite careful staging and advances in adjuvant therapy and surgical techniques, 
5-year survival rates rarely exceed  40%.1-2 Many patients present with locoregional recur-
rence and distant metastasis die within 2 years after curative esophagectomy.3 Treatment of 
patients with local disease recurrence aims at relieving dysphagia.  
Studies have shown that luminal patency is restored in the majority of patients with inop-
erable malignant stenosis by placing a self-expandable metal stent (SEMS).4  SEMSs are also 
effective in sealing esophago-respiratory fistulae.5 They are technically easy to insert, and 
placement is successful in close to 100% of patients. Although SEMS placement is a minimally 
invasive procedure,6-8 it carries the risk of severe complications, including perforation, hemor-
rhage, stent occlusion, and migration.9-10 In 40% of patients, dysphagia recurs because of 
stent migration and tissue in- and overgrowth.11
The clinical efficacy of SEMSs in patients with dysphagia or fistula caused by recurrent 
cancer after esophagectomy is not well documented. We therefore assessed the safety and 
efficacy of SEMS insertion in a cohort of patients with this condition.
METHODS
This prospective observational study was conducted in a large tertiary referral center and 
was approved by the institutional research committee. Between 1994 and 2009, all patients 
with dysphagia or respiratory fistula caused by recurrent malignancy after previous surgical 
esophagectomy were included when undergoing SEMS placement. Exclusion criteria were a 
tumor length of more than 13 cm or a lesion within 2 cm of the upper esophageal sphincter.
Demographic data and clinical data were prospectively collected in a database. At 4 weeks 
after stent placement, patients were contacted by telephone. In case of complications or 
stent dysfunction patients were seen for evaluation and subsequent intervention. The gen-
eral practitioner was contacted in case of missing follow-up information. 
A variety of partially and fully covered SEMSs were inserted. These stents consisted of 
woven, knitted, zig-zag, or laser-cut metal mesh cylinders. After release, they continued to 
expand until they reached the preset maximum expanded diameter. Stent bodies had an 
internal diameter ranging from 17 to 20 mm. Small-diameter stents were SEMSs with an 
internal body of 18 mm or less. 
The type of stent was selected depending on the availability at that time and the physi-
cians’ preference.  The length of the SEMS was selected according to the size and location of 
the obstruction with the proximal and distal funnel extending approximately 2 cm outside 
the stenosis. SEMSs were placed under endoscopic and fluoroscopic control, in accordance 
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with a standard protocol.11 Immediately after the procedure, a small amount of clear liquid 
was given by mouth to evaluate passage, retrosternal pain, and aspiration. Dysphagia was 
scored before SEMS insertion according to the following classification: 0 = ability to eat a 
normal diet, 1 = ability to eat some solids, 2 = ability to eat semisolids only, 3 = ability to 
swallow liquids only, 4 = complete dysphagia.12 Technical success was defined as dysphagia 
grade 0 or complete closure of the fistula with improvement of aspiration symptoms within 
7 days after stent placement. Stent dysfunction was classified as incomplete sealing of the 
esophageal leak or dysphagia caused by stent migration, stent obstruction or tumor in- and 
overgrowth. Complications were defined as either mild or severe according to published 
criteria.11 Severe complications included perforation, fistula, aspiration pneumonia, stridor, 
and haemorrhage. Mild complications included either retrosternal pain and symptomatic 
gastroesophageal reflux. All patients were followed until death.
Statistical analysis
Numerical data were expressed as mean and standard deviation or median and the inter-
quartile range, as appropriate. Student t test, the chi-square test, and Pearson’s correlation 
or their nonparametric equivalents were used when appropriate. A Cox regression model 
was used to explore the effect of the variables on time until complications occurred or re-
current dysphagia/leakage. The Kaplan-Meier method was used to calculate survival from 
the date of stent insertion until the date of death. Statistical analyses were conducted using 
SPSS software version 15.0 (SPSS Inc, Chicago, Ill). Two-sided P values <0.05 were considered 
significant.
RESulTS
Patient characteristics
In 81 esophagectomy patients, a total of 100 esophageal SEMSs were inserted for pallia-
tion of recurrent tumor growth. Baseline patient characteristics are summarized in Table 1. 
Tumor recurrence became apparent at a median interval of 17 months after esophageal 
resection (range 2 months – 10 years). Lesions were classified histologically as squamous 
cell carcinomas in 31% and adenocarcinomas in 69%. Ten (12%) patients previously received 
radiotherapy, 17 (21%) chemotherapy, and 15 (19%) received both radiotherapy and chemo-
therapy after the diagnosis of recurrent cancer. On inclusion, 66 (81%) patients presented 
with dysphagia, and 15 (19%) patients had a malignant esophagogastric respiratory fistula. 
In 50 (62%) patients, the tumor was located within 4 cm of the upper esophageal sphincter. 
Eighteen (22%) patients had recurrence extending into the proximal esophagus, 32 (40%) 
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patients at the anastomosis, and 31 (38%) patients distal to the anastomosis in the tubular 
stomach. Fifty (62%) patients had an intrinsic stenosis, and 16 (20%) had extrinsic esophageal 
compression caused by mediastinal metastasis. Forty-nine (60%) patients initially received a 
partially covered stent; all others (40%) received a fully covered stent (Table 2). In our study, 
78% of patients received a small-diameter stent, all other stents were large diameter.
Stent therapy 
Luminal patency 
The median survival time after stenting for all patients with stenosis was 70 days (range 
1 day - 34 months). Stent insertion was technically successful in all but one patient (98%) 
TABLE 1. Baseline characteristics of patients
Age, y, mean ± SD 62 ± 11
Sex, no. (%)
   Male
   Female
61 (75)
20 (25) 
Stent indication, no. (%)
   Dysphagia                                                                                
   Fistula
66 (81)
15 (19)
Tumor length, cm, mean ± SD 6 ±  3
Tumor histology, no. (%)
   Adenocarcinoma
   Squamous cell carcinoma
56 (69)
25 (31)
Dysphagia score before treatment
   Grade 2
   Grade 3
   Grade 4
2 (2)
43 (54)
36 (44)
Previous radiation and/or chemotherapy, no. (%)
   Total
   Chemotherapy
   Radiation
   Radiation and chemotherapy
42 (52)
17 (21)
10 (12)
15 (19)
Tumor location
   ≤ 4 cm of the upper esophageal sphincter
   >4  cm of the upper esophageal sphincter
50 (62)
31 (38)
SD, Standard deviation.
TABLE 2. Stent type
Stent Type No. (%)
Ultraflex Partially covered 37 (46)
Niti-S Fully covered 14 (17)
Flamingo Wallstent Partially covered 12 (15)
Z-Stent Fully covered 11 (14)
Hanarostent Fully covered 6 (7)
Alimaxx-E Fully covered 1 (1)
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(Figure1). Median duration of primary stent patency was 56 days (range 1 day – 33 months) 
(Figure 2). A total of 20 episodes of stent dysfunction occurred in 18 (27%) of 66 patients at 
a median of 38 days post-SEMS insertion (range 2 – 406 days). Stent dysfunction was caused 
by tissue in- or overgrowth (n=8), stent migration (n=9), and food impaction (n=3). Tissue 
in- and overgrowth occurred at a median of 119 days post-SEMS insertion (range 33 – 297 
days); 5 patients were successfully treated with a second SEMS. Six (24%) of 25 fully covered 
stents versus 3 (7%) of 41 partially covered SEMS migrated (p=0.07) at a median time interval 
A B
Figure 1
A. Endoscopic view of recurrent malignant stenosis at the anastomosis after gastric interposition. 
B. Restoration of the luminal patency after SEMS insertion.
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 80 
60 
 40 
20 
  0    
Figure 2. Duration of luminal patency and fistula sealing in 81 consecutive patients with an esophageal SEMS for recurrent esophageal cancer.
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of 66 days after SEMS insertion (range 12 – 406 days). Of these patients, 6 patients required 
a second SEMS. Food bolus impaction occurred in 3 (20%) patients at a median interval of 
11 days after SEMS insertion; all 3 were successfully cleared endoscopically. Insertion of a 
second SEMS was successful in all patients (100%). Median patency of these stents was 59 
days (range 5 – 286 days).
Fistula sealing 
The median survival time of patients with malignant fistula caused by tumor recurrence was 
73 days (range 10 days – 91 months). The coated segment of the stent effectively sealed 
fistulae in all but 1 patient (93%). This patient was successfully treated with a second stent. 
Stent dysfunction occurred in 6 (40%) of 15 patients. In 5 (33%) patients, additional stents 
were successfully inserted to manage stent migration (n=4) and persistent leakage during 
stent treatment (n=1). Two out (22%) of 9 fully covered stents versus 2 (33%) of 6 partially 
covered SEMSs migrated at a median time interval of 5 months post-SEMS insertion (range 5 
days – 11 months). Food bolus impaction occurred in one patient 17 days post-SEMS inser-
tion, this patient was also successfully treated endoscopically by stent clearance.  
Overall complications and mortality 
Mild complications after stent placement occurred in 7 (9%) patients including retrosternal 
pain and symptomatic gastroesophageal reflux. Major complications occurred in 9 (11%) 
patients. Stridor developed immediately after insertion in 3 patients with a lesion within 4 
cm of the upper esophageal sphincter. In all 3 patients, the stent was removed, and they 
were managed conservatively. Three patients had an upper GI hemorrhage from the tumor 
site at a median time interval of 26 days after SEMS insertion (range 11 days – 10 months). 
The bleeding subsided spontaneously in 1 of these patients; the other 2 patients died of the 
persistent bleeding. An esophageal fistula developed during stent treatment in 2 patients, 
both of which were located at the distal funnel of the partially covered stent at a median 
time interval of 48 days post-SEMS insertion. These wall defects were successfully sealed with 
an additional stent. One patient had a stent-induced ulceration after stent migration at 7 
months after SEMS insertion and required endoscopic stent extraction. The overall 30-day 
mortality rate after stent insertion was 25%. Progression of the disease resulted in death after 
a median time interval of 70 days (range 1 day - 91 months). Variables including stenosis 
or fistula, histology, stent type, stent size, and previous therapy were not independently as-
sociated with the development of stent associated complications, recurrent dysphagia, or 
survival. Similar results were obtained when the variables were entered into a multivariate 
Cox regression model.
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DISCuSSION
Even after curative surgery, the median esophageal cancer-specific survival is only 38 months. 
The esophageal cancer-free survival rate at 1, 2, and 5 years reportedly is approximately 84%, 
65%, and 41%, respectively.1 Stenosis caused by locoregional recurrence or obstructive me-
diastinal metastasis develops in a subset of patients with cancer recurrence.3, 13-15 Although 
chemotherapy and radiotherapy can be effective for symptom relief for locoregional tumor 
recurrence, it can take as long as several weeks for such therapy to relieve dysphagia.16-17 
Given the short life expectancy in these patients, a more rapid relief is usually required. 
SEMSs have been successfully used since the early 1990s for palliation of primary esophageal 
cancer.12, 18-22 However, the efficacy of SEMS therapy in patients with recurrent cancer after 
esophagectomy is not well established. The current cohort study, which is the largest pub-
lished to date, shows a clear benefit of SEMS therapy in patients with recurrent tumor growth 
after esophagectomy. SEMS placement was effective in patients with intrinsic and extrinsic 
esophageal lesions and restored luminal patency in 98% of patients, which is comparable to 
previous smaller series.7, 15, 23 Recurrent dysphagia occurred in 27% of patients; all patients 
were successfully managed by endoscopic reintervention. 
Esophageal respiratory fistulae occur in 5% to 10% of patients with esophageal cancer.19, 24 
In our series, 19% of patients with recurrent cancer after gastric tube interposition presented 
with a fistula. This represents a devastating complication leading to recurrent pulmonary 
infections and the inability to eat or even swallow saliva. This condition is associated with a 
very high short-term mortality.25 The technical success of fistula sealing by SEMSs was 93%, 
which is within the range of the 80% to 100% reported by other series.19 In the majority of 
patients with cancer recurrence after esophagectomy, the fistula or stenosis is located close 
to the upper esophageal sphincter. At this location, SEMS placement may cause foreign 
body sensation, tracheal compression, or respiratory fistula.26-27 It has been hypothesized 
that stents should have a body diameter of 18 mm  or less to avoid these complications.4  In 
our series, however, stridor developed in 3 (4%) patients and a fistula developed in 2 (2%) 
patients after stent placement, despite the use of small-diameter stents in 4 of them. None of 
the patients reported globus sensation.
Approximately half of the patients had undergone chemotherapy and/or radiotherapy be-
fore stent insertion. The use of SEMSs in combination with chemotherapy and radiotherapy 
is controversial.11, 28-32 Kinsman et al. reported a complication rate of 36% and a mortality rate 
of 23% in patients with radiation and/or chemotherapy, compared with 3% and 0% respec-
tively, in patients without previous therapy.32 In our series, however, no differences were seen 
with respect to the incidence and character of complications and stent dysfunction between 
patients with or without previous chemo/radiotherapy.
Stent migration is one of the most frequently reported causes of stent dysfunction.  This 
was also the main cause of stent dysfunction in our series. The reported migration rate 
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ranges from 7% to 58%.33-36 Reportedly, fully covered stents are more prone to migration 
than partially covered stents. In our series, the overall difference in stent migration, 8 of 32 
fully covered versus 5 of 49 partially covered stents, was not statistical significant. The need 
for additional stents to manage stent dysfunction was considerable; in our series, nearly 1 of 
every 4 patients needed an additional stent. Other recent studies reported comparable or 
even higher numbers of additional stents to manage stent dysfunction.11, 20, 37-38 The reported 
median survival after cancer recurrence ranges from 7-16 months.3, 14 The recurrent tumor has 
often spread significantly before compromising the esophageal lumen or the patency of the 
wall. This may contribute to the short median survival of 70 days in our series. Various fac-
tors, such as stenosis or fistula, histology, stent type (partially vs fully covered), and previous 
therapy did not seem to influence survival. 
SEMS placement in recurrent esophageal cancer after surgical resection offers adequate 
palliation by relieving dysphagia and sealing off esophageal respiratory fistula. Therefore, in 
these patients who have a relatively short life expectancy, the implantation of SEMSs should 
be considered the treatment of choice.
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AbSTRACT
Background and study aims: In patients with primary esophageal cancer, luminal patency can 
be restored by placement of a self-expandable metal stent (SEMS). The use of SEMS in patients 
with dysphagia caused by malignant extrinsic compression has largely been unreported. In 
this study we evaluated the efficacy of SEMS in a large cohort of patients with malignant 
extrinsic compression. 
Patients and methods: This is a prospective single-center study. Between 1995 and 2009, 
50 consecutive patients with malignant extrinsic compression who had undergone SEMS 
placement were included (mean age 64 years; 37 males). In the majority of patients, extrinsic 
esophageal compression was caused by obstructive pulmonary cancer (n=23) and by medi-
astinal metastasis after esophagectomy for esophageal cancer (n=16).
Results: Stent placement was technically successful in all patients. Severe complications oc-
curred in 5/50 patients (10 %) including perforation during dilation prior to stent insertion
(n=2) and hemorrhage (n=3). Two patients (4 %) died from bleeding. Mild complications were 
seen in 9/50 patients (18 %). Recurrent dysphagia occurred in eight patients (16 %) and was 
successfully managed by subsequent endoscopic intervention. Median survival after stent 
placement was 44 days (range 5 days–2 years). The median stent patency of 46 days in this 
series exceeded median patient survival.
Conclusions: Insertion of a SEMS is an effective palliative treatment for patients with dysphagia 
due to malignant extrinsic compression. In spite of the short survival, some patients present 
with recurrent dysphagia, which can be managed effectively by endoscopic re-intervention. 
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INTRODuCTION
Most patients with dysphagia due to malignant extrinsic compression are incurable and have 
a life expectancy of less than 6 months after initial symptoms. Malignant extrinsic compres-
sion can be caused by pulmonary cancer, mediastinal cancer, metastatic disease, or local 
recurrence of cancer after esophagectomy.1-2 Treatment of patients with nonresectable ma-
lignant stenosis is palliative; by relieving dysphagia, nutritional intake can be maintained and 
quality of life improved.3 Studies have shown that luminal patency is restored in the majority 
of patients with esophageal cancer by placement of a self-expandable metal stent (SEMS). 
SEMS are technically easy to deploy and placement is successful in up to 100%. Although 
SEMS placement is a minimally invasive procedure,4-6 it can lead to several complications, 
including perforation, haemorrhage or ulceration.7-8 Dysphagia recurs in some patients, due 
to food bolus obstruction, stent migration and tissue ingrowth and overgrowth.9
Little is known about the results of SEMS placement in patients with dysphagia caused 
by malignant extrinsic compression. The aim of this study was to establish the safety and 
efficacy of SEMS placement in patients with this condition.
PATIENTS AND METHODS
This prospective trial was conducted in a large tertiary referral center and was approved by 
the institutional ethics committee. Between 1995 and 2009, all patients with dysphagia due 
to malignant extrinsic compression and who underwent SEMS placement were included. 
Exclusion criteria were a tumor length of more than 13 cm, and an obstruction within 2 cm of 
the upper esophageal sphincter. Diagnosis of extrinsic esophageal compression was based 
on radiologic and endoscopic imaging. Demographic data, clinical data, and procedural data 
were collected at inclusion. At 4 weeks after stent placement, patients were contacted by 
phone. In case of complications, or stent dysfunction patients were seen for evaluation and 
subsequent intervention. The general practitioner was contacted in cases of missing follow-
up information (e. g. due to death). 
Available stents were covered and had a body diameter ranging from 16 mm to 20 mm 
and a length ranging from 8 cm to 17 cm. The length of the SEMS was selected according 
to the size and location of the obstruction, with the proximal and distal funnel extending 
approximately 2 cm outside the stenosis. Selection of the type of stent was tailored to each 
particular case depending on the clinical situation, anatomic location of the lesion, and the 
physician’s preference.
Stents were placed under endoscopic and fluoroscopic control, according to a standard 
protocol. Immediately after the procedure, a small amount of clear liquid was given by mouth 
to evaluate passage, retrosternal pain, and aspiration. Dysphagia was scored prior to stent 
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insertion, according to the following classification: 0=ability to eat a normal diet; 1=ability to 
eat some solids; 2=ability to eat semisolids only; 3=ability to swallow liquids only; 4=complete 
dysphagia.10 Technical success was defined as successful stent deployment at the required 
position. Stent dysfunction was defined as dysphagia due to tissue ingrowth or overgrowth, 
stent migration or food bolus impaction. Complications were defined as either mild or severe 
according to published criteria.9 Severe complications included perforation, fistula, aspira-
tion pneumonia and haemorrhage. Mild complications included either retrosternal pain or 
symptomatic gastroesophageal reflux. All patients were followed until death.
Statistical analysis
Numerical data were described by using the mean with standard deviation or median with 
interquartile range, as appropriate. Functional and technical outcome, complications, stent 
patency, and survival were analyzed with chi-squared testing and Kaplan-Meier curves. 
Statistical analyses were conducted using SPSS software (SPSS 15.0, Chicago, Illinois, USA). 
Two-sided P-values of < 0.05 were considered to be significant. 
RESulTS
Patient characteristics
A total of 50 patients underwent esophageal stent placement for malignant extrinsic com-
pression. The mean age at stent insertion was 64 years (range 41-83 years). Baseline patient 
characteristics are summarized in Table 1. The following stents (n=54) were placed in a cohort 
of patients; 32 partially covered stents (59%) and 22 fully covered stents (41%). In the majority 
of patients, extrinsic esophageal compression was either caused by obstructive pulmonary 
cancer (n=23), or due to mediastinal metastasis after surgical resection for esophageal cancer 
(n=16). Other causes included mediastinal metastases of breast cancer (n=4) (Figure1), mela-
noma (n=2), thyroid carcinoma (n=1), sarcoma (n=1), synovia carcinoma (n=1) or metastasis 
of unknown origin (n=2). Of the 16 patients with mediastinal metastasis after esophagec-
tomy for esophageal cancer, five patients (31 %) had recurrence extending into the proximal 
esophagus, three patients (19 %) at the anastomosis, and eight patients (50 %) distal to the 
anastomosis in the tubular stomach. Four patients (8 %) with obstructive pulmonary cancer 
received an airway stent immediately prior to esophageal stent placement. Almost half of the 
patients had received radiation and/or chemotherapy prior to stent placement.
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Stent insertion and patency
In all patients, stent insertion was technically successful and adequately restored luminal pa-
tency. Stent dysfunction occurred in eight patients (16 %) – four of the 32 patients with par-
tially covered stents (13 %) and four of the 22 with fully covered stents (18 %) (Table 2). Stent 
dysfunction occurred at a median time interval of 46 days post-SEMS insertion (range 2–406 
days). Three patients experienced food bolus impaction within 1 week of stent placement; 
they were successfully treated endoscopically. Two additional stents were inserted for tumor 
overgrowth at 28 and 119 days, respectively, post-SEMS insertion. One partially covered and 
TABLE 1. Baseline characteristics of patients
Age, y, mean ± SD 64 ± 10
Sex, no. (%)
   Male
   Female
37 (74)
13 (26)
Stenosis length, cm, mean ± SD 5 ± 3
Dysphagia score before treatment
   Grade 2
   Grade 3
   Grade 4
2 (4)
31 (62)
17 (34)
Origin of malignancy, n (%)
   Pulmonary carcinoma
   Esophageal cancer
   Mamma carcinoma
   Others
23 (46)
16 (32)
4 (8)
7 (14)
Prior radiation and/or chemotherapy, n (%)
   Total
   Chemotherapy
   Radiation
   Radiation and chemotherapy
21 (42)
12 (24)
5 (10)
4 (8)
A B
Figure 1. A 74-year-old patient presented with grade 3 dysphagia, due to mediastinal breast cancer metastases. 
A. Endoscopic view. 
B. A partially covered stent was placed into the esophagus.
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one fully covered stent migrated and were both removed and replaced by partially covered 
Ultraflex stents at 195 and 406 days respectively, post initial SEMS placement. One patient 
was successfully treated for hyperplastic tissue ingrowth with argon plasma coagulation at 
58 days post-SEMS insertion. The duration of stent patency was not significantly associated 
with age, prior therapy or stent type (partially covered vs. fully covered). In the two patients 
with an esophageal perforation caused by prior dilation of the stenosis, the fistula was suc-
cessfully sealed with the covered SEMS.
Complications
A total of 12 complications occurred during stent treatment. In nine patients (18 %) mild 
complications including retrosternal pain and symptomatic gastroesophageal reflux oc-
curred within 5 days of SEMS insertion. Hemorrhage was the only severe stent-related com-
plication encountered, and was fatal in two patients. One patient with extrinsic compression 
due to metastatic synovial sarcoma with tumor growth through the esophageal wall had a 
self-limiting tumor bleed 12 days post-SEMS insertion. Two patient died of a massive gastro-
intestinal bleed within 7 days post-SEMS insertion.
TABLE 2. Recurrent dysphagia in 50 patients with extrinsic compression
Stent brand n (%)* Covering Recurrent dysphagia, n (%)
Ultraflex stent 28 (52) Partially covered Total: 4 (14)
   Tumor overgrowth, 1
   Tissue ingrowth, 1
   Stent migration, 1
   Food bolus obstruction, 1
Z-Stent 9 (17) Fully covered Total: 1 (11)
   Food obstruction, 1
Niti-S stent 8 (15) Fully covered Total: 2 (25)
   Stent migration, 1
   Food bolus obstruction, 1
FlamingoWallstent 4 (7) Partially covered Total: 0 (0)
Alimaxx-E stent 2 (4) Fully covered Total: 0 (0)
Hanarostent 1 (2) Fully covered Total: 1 (1)
  Tumor overgrowth, 1
Polyflex 1 (2) Fully covered Total: 0 (0)
SX-Ella stent 1 (2) Fully covered Total: 0 (0)
*In total, 54 stents were placed.
Ultraflex stent, Boston Scientific, Natick, Massachusetts, USA
Z-Stent, Cook Medical, Bloomington, Indiana, USA
Niti-S stent, Taewong Medical, Seoul, Korea
FlamingoWallstent, Boston Scientific
Alimaxx-E stent, Alveolus Inc., Charlotte, North Carolina, USA
Hanarostent, MI Tech, Seoul, Korea
Polyflex, Rüsch AG, Kernen, Germany
SX-Ella stent, Ella-CS, Hradec Králové, Czech Republic
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Survival
The 30-day mortality rate after stent insertion was 36%. Progression of disease resulted in 
death in all patients after a median interval of 44 days (range 5–774 days) (Figure 2).
DISCuSSION
The palliative management of patients with a malignant esophageal obstruction is a clinical 
challenge. The gastroenterologist has to balance the benefits of restoring luminal patency 
by SEMS on patients’ quality of life in the context of a short life-expectancy, with the risk 
of procedural complications. Although chemotherapy and radiotherapy are sometimes 
beneficial, they may require several weeks to improve dysphagia 11. Generally, a more rapid 
relief of dysphagia is required. Currently, SEMS placement is the most widely used palliative 
treatment in patients with malignant dysphagia.12 This immediately restores luminal patency 
and thereby improves oral intake and quality of life.3, 13-14 The efficacy of SEMS in patients with 
extrinsic compression however, has not been well established. 
Figure 2. Kaplan-Meier curve: overall survival of 50 patients after stent placement. SEMS, self- expandable metal stent.
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More than a decade ago, two limited series were published describing stent therapy in 
patients with malignant extrinsic compression using non-covered SEMS. Bethge et al. com-
pared stent placement therapy in 24 patients with dysphagia caused by esophageal cancer 
versus stent therapy in 22 patients with extrinsic compression. Dysphagia improved in both 
groups. However, a significantly greater improvement was observed in patients with intrinsic 
stenosis. The mean survival time in patients with extrinsic compression was 89 days.15 In the 
second series, by Gupta et al., stents were placed in 17 patients with extrinsic compression, 
leading to an improvement of dysphagia in all but one patient (94%). Recurrent dysphagia 
occurred in four patients (24%), major complications in one (6%), and minor complications 
in four patients (24%). Mean survival time was 63 days.5 Most of the stents used in these 
series were uncovered, a feature that has more recently been associated with shorter stent 
patency in patients with intrinsic malignant strictures.16 To date, there are no published series 
evaluating covered SEMS for extrinsic malignant stenosis. 
In the majority of patients, dysphagia due to malignant extrinsic compression is caused 
by pulmonary carcinoma or by the recurrence of esophageal cancer after surgery.5, 15 SEMS 
insertion is a relatively easy procedure in most patients with primary esophageal cancer, 
with a success rate as high as 100%.1, 17-18 In this cohort too, procedural success was 100%. 
Procedure-related complications occurred in two patients at endoscopic dilatation of a tight 
stenosis prior to stent insertion. These perforations were successfully sealed with the covered 
SEMS. 
One of the most frequently reported causes of stent dysfunction is stent migration, which 
reportedly ranges between 7% and 58%.16, 19-21 Migration is influenced by several factors. 
Partially covered stents reportedly tend to migrate less often than fully covered stents, 
and uncovered segments rapidly become embedded into the mucosal wall.22 Chemo- or 
radiotherapy after SEMS insertion also increases the risk of migration by reducing the tumor 
mass.23 Therefore, the use of SEMS in combination with chemotherapy or radiotherapy is 
controversial.19, 24-27 In this series stent migration occurred in only 4% of patients (one fully and 
one partially covered stent). Based on this observation, we cannot exclusively recommend 
the use of partially covered stents in these patients. The low migration rate can be partly 
explained by the short median survival, but furthermore likely resulted from the fact that 
most patients suffered from a considerable tumor mass adjacent to the esophagus which 
thus offered firm fixation of the inserted stent.
Another common cause of stent dysfunction in primary gastroesophageal cancer is stent 
occlusion by tumor ingrowth or overgrowth, which in published series ranged from 25% to 
40%.4, 19, 27-29 The incidence of tissue ingrowth is higher with the use of partially covered stents 
than with fully covered stents. As all malignancies were located extrinsically in our series, 
we saw no dysphagia due to malignant tissue ingrowth. In one patient stent occlusion was 
caused by the growth of benign hyperplasic tissue through the uncovered distal segment. 
This was successfully managed with argon plasma coagulation. The literature shows that the 
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use of SEMS in patients with intrinsic esophageal cancer has led to severe complications, 
including hemorrhage, abscess formation, and an aorta-esophageal fistula.3, 30-32 In our series, 
three severe complications occurred, all severe hemorrhages, two of which were fatal. This is 
remarkable as the esophageal narrowing was caused by a tumor located extra-esophageal 
and most bleeds during stent therapy are thought to result from a tumor bleed.1, 7 In a recent 
series in which self-expandable plastic stents were placed for benign esophageal stenosis, 
therapy was also complicated by bleeding in one patient and resulted in death.33 Therefore 
it is not only the tumor that can lead to severe bleeding but also erosion and necrosis of the 
esophageal wall into major vessels.33-34 
Bethge et al. reported a shorter survival time in patients with extrinsic compression (89 
days) compared to patients with intrinsic tumors (163 days).15 Survival after placement is 
obviously a function of the timing of stent insertion in relation to the disease stage. In our 
series, 96% of patients had grade 3-4 dysphagia on inclusion. Median survival time in our 
series was only 44 days. In patients with extra-esophageal tumors, the tumor has to have 
spread and grown substantially in order to compromise the esophageal lumen. This may ex-
plain the relatively short survival period of these patients over that of patients with intrinsic 
esophageal tumors.19, 29 In our series, the type of stent (partially vs fully covered) and radiation 
and/or chemotherapy prior to stent placement, did not influence the clinical outcome.
In conclusion, our results demonstrate that despite a particular poor life expectancy, 
insertion of self-expandable metal stents offers good palliation in patients with dysphagia 
caused by malignant extrinsic esophageal compression. In spite of the short survival, some 
patients present with recurrent dysphagia an this can be managed effectively by endoscopic 
re-intervention.
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AbSTRACT
Objectives: Self-expanding metal stents (SEMS) provide effective palliation in patients with 
malignant dysphagia. However, although life expectancy is generally limited, reintervention 
rates due to stent dysfunction are significant. New SEMS are being designed to overcome this 
drawback. In the present study, we aimed to assess whether the new design Evolution stent 
is superior to the conventional Ultraflex stent for the palliative management of patients with 
malignant dysphagia or esophageal fistulae.
Methods: In a multi-center randomized clinical trial, consecutive patients with stenosis or fis-
tula due to malignant esophageal disease were randomized to placement of a conventional 
Ultraflex® stent or the new Evolution® stent. Patients were followed by scheduled telephone 
calls at one and three months after SEMS insertion. 
Results: A total of 80 patients (73% male; median age 67 years (range: 40-92 years)) were 
included. One patient refused follow-up. Technical success was 100% in both groups. Re-
intervention rate was 15/40 (38%) for the Ultraflex and 4/39 (10%) for the Evolution stent 
(p=0.004). Major complications including aspiration pneumonia and bleeding occurred more 
frequently with the Ultraflex stent (10/40 (25%)) compared to the Evolution stent (3/39 (8%)) 
(p=0.04). There was no difference in overall survival between the two groups.
Conclusions: The Ultraflex stent and Evolution stent are equally effective in the relief of malig-
nant dysphagia and sealing fistulae. Ultraflex stent is associated with more stent dysfunction 
and a significantly higher major complication rate. Patients treated with an Evolution stent 
also needed significantly fewer reinterventions than those treated with an Ultraflex stent. 
This sets the preference for the Evolution stent over the Ultraflex stent for patients with 
malignant esophageal disease.
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INTRODuCTION
Esophageal cancers are among the leading causes of cancer-related death worldwide. The 
incidence of esophageal carcinoma is rising rapidly in developed countries because of an 
increase in the frequency of adenocarcinoma.1 The 5-year survival of patients with esopha-
geal cancer remains below 20% despite multimodality treatment and concentration of care. 
The majority of patients with esophageal cancer have inoperable disease at presentation. In 
these patients palliative therapy is the only treatment option. Placement of a self-expandable 
metal stent (SEMS) is a rapid means to restore luminal patency and/or to seal esophageal 
fistulae. Nutritional intake can be effectively restored, thereby significantly improving the 
quality of life.2-3 Ideally this is accomplished in a single procedure, without the need for ad-
ditional procedures (reinterventions) within the limited further life-span of these patients. 
A wide variety of expandable esophageal endoprostheses have been developed to im-
prove therapeutic outcome and to reduce the need for endoscopic reintervention during 
the course of the disease. Unfortunately, reinterventions remain common.4-6 Currently, the 
Ultraflex® stent is worldwide most frequently used. The Evolution® stent has recently been 
introduced as an alternative with modified characteristics, including adaptations in the deliv-
ery system, flares, diameter and covering. In this prospective randomized study, we aimed to 
assess whether the new design Evolution stent is superior to the conventional Ultraflex stent 
for the palliative management of patients with malignant dysphagia or esophageal fistulae. 
METHODS
Study design and patients
STEnts for esophageal MAlignant disease (STEMA) trial was a randomized open multicenter 
trial. Patients were eligible for inclusion if they had inoperable esophageal cancer, compli-
cated by esophageal stenosis and/or fistula formation, with an indication for permanent 
stent insertion. Patients were ineligible for inclusion if they presented with lesions within 2 
cm from the upper esophageal sphincter, lesions longer than 11 cm, or with active bleeding 
at endoscopy. 
Stent placement was performed in two hospitals, the Erasmus MC University Medical 
Center Rotterdam and the Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, 
Amsterdam the Netherlands. The ethical committees of both participating centers approved 
the study. All patients provided written informed consent before enrolment. 
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Randomization  
Patients were randomly assigned (1:1) to Ultraflex stent or Evolution stent insertion. Ran-
domization was done by computer-generated blocks of 10, stratified by centre. Patients 
and investigators were not masked to treatment allocation. All authors had full access to all 
the data in the study and had shared responsibility for the decision to submit the report for 
publication.
SEMS and stent insertion procedures
Patients were treated with an Ultraflex stent or an Evolution stent (Figure 1). The Ultraflex 
stent (Boston Scientific, Natick, MA) consists of a partially covered knitted nitinol wire tube. 
The cover consists of a polyurethane layer that covers the midsection of the stent extending 
up to 1,5 cm on each end. The stent is available in 3 lengths: 100 mm, 120 mm and 150 mm. 
The stent has a body diameter of 18 mm and a proximal flare with a diameter of 23 mm. 
The Evolution stent (Cook Medical, Limerick, Ireland) has a pistol-grip delivery system that 
allows controlled release while the stent can be recaptured during release. The “lasso” loop 
on the proximal end enables stent repositioning and removal after placement. The cover 
consists of a silicone layer that covers the midsection of the stent extending up to 1,5 cm 
A B
Figure 1. Stents used in this trial: Ultraflex stent (A) Evolution controlled release stent (B)
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on each end. The stent has a body diameter of 20 mm and two distal flanges of 25 mm in 
diameter. The stent is available in 4 lengths: 80, 100, 125 and 150 mm. 
All procedures were performed under conscious sedation. The lesion was inspected us-
ing a flexible video endoscope. The distance between the dental incisors and the proximal 
border of the tumor and the length of the lesion were measured. Stent length was based on 
the length of the lesion; the stent length was chosen at least 3 cm longer than the stricture 
length, to allow for deployment of the flanges above and below the proximal and distal 
tumor shoulder. The stent was positioned over a guidewire and deployed under fluoroscopy. 
One hour after the procedure patients were given a small amount of clear liquid by mouth to 
evaluate passage, retrosternal pain and aspiration. Resumption of oral intake was permitted 
on the day of implantation.
Study outcomes
The primary outcome was the 90-day endoscopic reintervention rate. Secondary outcomes 
were technical success, stent dysfunction, complications and survival. Dysphagia was 
scored prior to SEMS insertion and 30 days thereafter, according to the following Atkinson 
Dysphagia was scored prior to SEMS insertion and 30 days thereafter, according to the fol-
lowing Atkinson Dysphagia Score; 0=ability to eat a normal diet, 1=ability to eat some solids, 
2=ability to eat semisolids only, 3=ability to swallow liquids only, 4=complete dysphagia.7 
Technical success was defined as dysphagia improvement or complete closure of the fistula 
with improvement of aspiration symptoms after stent placement. Stent dysfunction was 
classified as incomplete sealing of the esophageal leak, recurrent dysphagia, e.g. due to stent 
migration, stent obstruction or tumor overgrowth. Complications were defined according 
to the published nomenclature for classification of complications.8 Severe complications 
included perforation, fistula, (aspiration) pneumonia, stridor and overt haemorrhage. Mild 
complications included retrosternal pain, symptomatic gastro-esophageal reflux or foreign 
body sensation. 
Follow-up
Patients were evaluated prior to stent placement, at 30 and 90 days after SEMS insertion by 
scheduled telephone interviews, until new stent placement or death. In case of complica-
tions or stent dysfunction, patients were seen for re-evaluation. All evaluation items were 
recorded in the case record form.
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Randomization
We calculated that a sample size of 80 would provide 80% power to detect a relative reduc-
tion in reintervention rate by at least 50% in favor of the new stent design.9 All analyses were 
based on the intention-to-treat principle. For comparison of baseline characteristics, differ-
ences in continuous variables were analyzed by t tests, and differences in categorical variables 
by χ² tests. Complications and recurrent dysphagia in the two groups were compared with 
Kaplan-Meier and log-rank tests to adjust for time of occurrence of the event and survival 
differences. Survival of the two groups was calculated and compared using Kaplan-Meier 
curves and log-rank test. A significance level of 0.05 with two-sided testing was used, and all 
analyses were performed in SPSS® version 17 (IBM, USA). 
RESulTS
Patient characteristics
Between June, 2009, and January, 2011 a total of 80 consecutive patients with malignant 
esophageal stenosis or fistulae due to malignant disease were randomized to either the 
Ultraflex stent or the Evolution stent group. Table 1 shows the baseline characteristics of the 
Table 1: Baseline characteristics
Ultraflex stent (n=40) Evolution stent (n=40)
Age (years, mean (SD)) 67 (12) 67 (10)
Men/women 32/8 26/14
Dysphagia score before treatment (mean (SD)) 2.9 (0.8) 3.1 (0.6)
Tumor location from incisor teeth (cm, mean (SD)) 33 (7.0) 28 (6)
Length stent (cm, mean (SD)) 11.3 (1.8) 11.0 (2.8)
Indications for palliative treatment
   Metastasis
   Esophageal cancer
2 (5)
38 (95)
5 (13)
35 (87)
Tumor histology
   Squamous cell carcinoma
   Adenocarcinoma
   Other
8 (20)
30 (75)
2 (5)
15 (38)
20 (50)
5 (13)
Esophagorespiratory fistula
   Yes
   No
4 (10)
36 (90)
3 (8)
37 (92)
Previous chemo and/or radiotherapy
   Yes
   No
30 (75)
10 (25)
25 (63)
15 (37)
Data are numbers (%) unless otherwise specified 
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two groups. Study groups were similar in terms of all baseline clinical- and procedural charac-
teristics. Indications for stent therapy included primary esophageal cancer (n=73, 91%), and 
mediastinal metastasis of pulmonary cancer and breast cancer (n=7, 9%). Prior to inclusion 
8 patients had received radiotherapy (10%), 15 chemotherapy (19%), and 32 both (40%). On 
inclusion 73 (91%) presented with dysphagia (Figure 2a), and 7 patients (9%) had a malignant 
esophago-respiratory fistula. In 11 patients (14%), the tumor was located within 2-4 cm of the 
upper esophageal sphincter. 
Stent therapy
In this cohort, 40 (50%) Ultraflex stents and 40 (50%) Evolution stents were placed (Figure 2b). 
The initial stent insertion procedure was performed without any procedure related and was 
A B
DC
Figure 2. A. Endoscopic view showing malignant esophageal stenosis in the distal esophagus. B. The Ultraflex stent was positioned over 
a guidewire and deployed under endoscopic view, showing full expansion after placement. C. Granulomatous tissue growth in the distal 
uncovered segment, 6 weeks after placement of an Ultraflex stent. D. Food bolus obstruction.
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technically successful in all patients (100%). One (1%) patient with an Evolution stent refused 
follow-up.  
A statistically significant difference was observed between two stent groups for the pri-
mary outcome. Fifteen (38%) patients required endoscopic reintervention within 90 days 
after Ultraflex stent placement, versus 4 (10%) patients after Evolution stent placement 
(p=0.004). Table 2 shows the reinterventions performed. In these 19 (24%) patients, a total of 
22 reinterventions were performed to manage persistent dysphagia (n=1), recurrent leakage 
(n=1), stent migration (n=4), tissue in- or overgrowth (n=9) (Figure 2c), or food obstruction 
(n=7) (Figure 2d). Recurrent symptoms of leakage or dysphagia occurred more frequently in 
the Ultraflex stent group than in the Evolution stent group (n=16 vs n=3, p<0.001). 
Tumor overgrowth and stent migration were mostly managed by placement of a second 
stent and food obstruction by endoscopic desobstruction.
After 30 days, the Atkinson Dysphagia Score had improved from a mean of 3.0 to 0.5 in both 
study groups. In a multivariate analysis variables including the indication for stent therapy, 
prior therapy, and stent location were not independently associated with the therapeutic 
outcome in both groups.
TAblE 2. Complications and persistent or recurrent dysphagia after stent placement
ultraflex stent (n=40) Evolution stent (n=39) P
Endoscopic reinterventions 15 (38%) 4 (10%) 0.004
   Desobstruction 7 0 -
   Radiotherapy 1 0 -
   Stent removal 3 2 -
   Extra stent placement 7 2 -
   Balloon dilation 1 0 -
Stent dysfunction 16 (40%) 3 (8%) <0.001
   Persistent dysphagia 0 1 -
   Migration 3 1 -
   Tissue in- or overgrowth 8 1 -
   Food bolus obstruction 7 0 -
   Leakage 1 0 -
Total complications 15 (38%) 10 (26%) 0.257
Major complications 10 (25%) 3 (8%) 0.038
   (aspiration)pneumonia 3 2 -
   Severe pain 0 1 -
   Hemorrhage 7 0 -
Minor complications 5 (13%) 7 (18%) 0.500
   Mild retrosternal pain 5 5 -
   Gastroesophageal reflux 0 1 -
   Foreign body sensation 0 1 -
*More than one complication arose in some patients.
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Complications
With respect to the overall complications at 3 months, a total of 15 complications (38%) oc-
curred in patients randomly assigned to the Ultraflex group, versus 10 (26%) in the Evolution 
group (p=0.26) (Table 2). Thirteen complications were major and 12 were minor. Significantly 
more Major complications occurred after Ultraflex stent placement than after Evolution stent 
placement (p=0.04). Complications consisted predominantly of hemorrhage, which occurred 
in 7 patients after Ultraflex stent insertion compared to none of the patients treated with an 
Evolution stent. Bleeding resolved spontaneously in all patients. Two patients required blood 
transfusion. Five patients developed a (aspiration) pneumonia after stent placement; two of 
them died as a consequence, despite antibiotic treatment. 
No significant differences were noted between the two groups with respect to the inci-
dence of mild complications. Mild complications included pain, gastroesophageal reflux 
and foreign body sensation. One patient in the Evolution treated group demanded SEMS 
removal because of severe chest discomfort, in all others (n=10) retrosternal pain was treated 
effectively with analgesics. 
Survival
Median follow-up was 77 days (range: 1-90 days) after Ultraflex stent and 75 (range: 1–90 
days) after Evolution stent placement (p=0.23;  Figure 3). Thirty-nine patients were followed 
until death, 10 until stent replacement and 30 until 90 days of follow-up. By the end of follow-
up, 36 patients had died from tumor progression, 2 from aspiration pneumonia, and 1 from 
complications of recurrent esophageal leakage. The 30-day mortality did not differ between 
groups (Ultraflex n=10 versus Evolution n=7, p=0.45)
Figure 3: Overall stent survival after treatment.
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DISCuSSION
This randomized controlled trial in patients with malignant esophageal stenosis and esoph-
ago-respiratory fistula compared the most frequently used Ultraflex stent with the newly 
designed Evolution controlled release stent. Stent placement was successful in all patients in 
both study arms, and both stents were equally effective in improving food intake. However, 
placement of an Evolution stent was in comparison with the Ultraflex stent associated with 
lower reintervention rates and fewer major complications. 
In the Ultraflex group, 38% of patients required one or more interventions to manage stent 
dysfunction within 90 days after initial stenting, which is in line with previous published 
series.10-12 Yet, only 10% of patients in the Evolution group required endoscopic re-interven-
tions. The latter is low compared with the literature on malignant esophageal stenting. To 
date no comparative studies have been published with the Evolution stent, but one recent 
uncontrolled study with this new device reported a 25% dysphagia recurrence at a median 
survival of 88 days.13 
Endoscopic reinterventions are generally associated with patients burden, as well as sig-
nificant costs and risks. They have a negative impact on the quality of life, even when they are 
frequently successful.10 The majority of our patients needed additional treatment for tumor 
overgrowth or food bolus obstruction. Food impaction only occurred after Ultraflex stent 
placement, which may be due to the smaller stent diameter. Previous series have reported 
similar association between stent size and the risk of food bolus obstruction.14 While oth-
ers noted stent migration as predominant cause of stent dysfunction, migration was only 
observed with 8% of the Ultraflex stents and 3% of the Evolution stents. 9, 11, 15  This is at the 
lower end of the reported 4-18% migration rate of the Ultraflex stent and the 5% migration 
rate of the Evolution stent.13, 16-17 
The observed overall complication rate of 32% in our series is substantial, yet in the middle 
of the range in recent reports.18-20 In our series major complications arose more often after 
Ultraflex stent placement. The most common complication was hemorrhage, remarkably this 
only occurred in the Ultraflex stent group. 
The reported rate of stent procedure-related mortality is up to 54%, which is higher than in 
our study (3%).15, 18, 21 Within 1 month after SEMS insertion, two patients died from aspiration 
pneumonia and sepsis despite administration of antibiotics. Minor complications including 
retrosternal pain following stent placement requiring administration of analgesic medica-
tion are frequently observed and resolve spontaneously in the majority of patients within 
a few days.4, 22-23 Persistent severe pain is uncommon and was observed in one patient after 
proximal stent placement, this stent was successfully removed after 23 days. Complications 
were not related to stent location or prior therapy, which accords with results elsewhere.4, 12, 24 
However, this latter finding is in disagreement with some other reports.23, 25-26 
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The success rate of placement was 100% in both study groups. Apparently the type of 
introduction system did not influence the placement outcome. Stent placement resulted in 
sealing off esophagorespiratory fistulae and restoring luminal patency in all but one patients. 
There were no significant differences between the two stents in the improvement of dyspha-
gia or fistulae sealing at 1 and 3 months interval.
The observed benefits in the performance of the Evolution stent may likely be ascribed to 
the new stent design and resulting physical characteristics. The Evolution stent has a higher 
hoopstrength (radial force) than the Ultraflex, it has silicone internal and external coatings 
to prevent ingrowth, large dual flanges to prevent migration, and a larger stent diameter to 
avert food-bolus obstruction. 
To our knowledge, previous randomized controlled trials with the Ultraflex endoprosthesis, 
did not show any significant differences in therapeutic outcome between two types of SEMS. 
In the first randomized controlled trial, Siersema et al. compared the Ultraflex stent, Flamingo 
Wallstent and Gianturco-Z stent, and observed no clear differences in complication and 
recurrent dysphagia rate.17 Sabharwal et al. compared the Ultraflex stent with the Flamingo 
Wallstent. The two SEMS types showed similar efficacy in relieving malignant dysphagia 
and were associated with similar complication rates.5 In a more recent series, Conio et al. 
compared the self-expandable metal Ultraflex stent with the self-expandable plastic Polyflex 
stent in 100 patients with a malignant esophageal disease, with a significant higher com-
plication rate in the plastic stent group, leaving covered SEMS as the treatment modality of 
choice for patients with malignant esophageal disease.16
The strengths of this study include its prospective randomized design and high rate of 
follow-up evaluation (99%). The study is relatively large thereby providing the power to reach 
statistical significance in primary and secondary parameters. Performance of the study at a 
two institutions over a short period of time with expert endoscopists in SEMS placement 
assured relative uniformity of care to minimize confounders. Follow-up evaluation of patients 
by telephone interview at scheduled time intervals enabled us to capture all complications 
that occurred after discharge. A potential weakness is the inclusion of patients with either 
stenosis or fistula into the study, as these symptoms pose different demands to the perfor-
mance of the stent, and thereby to the design. Yet only seven patients presented with fistula, 
equally divided over both groups. This subgroup was too small to allow for subgroup com-
parison. Another weakness is that our follow-up was limited to 90 days post stent insertion. 
In this study 30 patients were still alive with their initial stent in situ at this end-point (38%). 
Evaluation of stent performance after reaching this endpoint is often more difficult, as the 
clinical condition often prohibits reintervention, and the ability to swallow becomes increas-
ingly difficult to analyze in view of tumor progression and the declining clinical performance. 
In conclusion, the present study indicates that the Ultraflex stent and Evolution stent are 
equally effective in the relief of malignant dysphagia and sealing fistulae. However, Ultraflex 
stent placement is associated with more stent dysfunction and a significantly higher major 
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complication rate. Patients treated with an Evolution stent also needed significantly fewer 
reinterventions than those treated with an Ultraflex stent. This sets the preference for the 
Evolution stent over the Ultraflex stent for patients with malignant esophageal disease. 
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AbSTRACT
Background: Self-expandable metals stents (SEMSs) have increasingly been used as a tempo-
rary device to bridge chemoradiotherapy in patients with malignant esophageal disease or 
in patients with benign esophageal defects or stenosis.
Objective: To evaluate the outcome of removal of SEMSs in a large cohort of patients with 
benign and malignant esophageal disease.
Design: Observational study with standardized treatment and follow-up.
Setting: Single university center.
Patients: Between 2001 and 2010, 95 consecutive patients referred for endoscopic SEMS 
extraction were included.
Interventions: Endoscopic stent removal.
Main Outcome Measurements: Technical and functional outcome and complications.
Results: A total of 124 stent extractions were undertaken in 95 patients; both partially covered 
(68%) and fully covered (32%) SEMSs were removed. Three patients had 2 overlapping SEMSs 
in place. Successful primary removal was achieved in 89%; the secondary removal rate was 
96%. Uncomplicated primary removal rate was significantly higher for fully covered versus 
partially covered stents (P= 0.035) and for single versus overlapping stents (P = 0.033). Pa-
tients with a complicated stent removal had the stent in place significantly longer compared 
with patients with an uncomplicated primary stent removal (126 days vs 28 days; P = 0.01). 
Surgical removal was required in 3 patients (2.4%). Six moderate and severe complications 
(5%) related to the endoscopic extraction occurred.
Limitations: Retrospective, nonrandomized study design.
Conclusions: Primary endoscopic removal of an SEMS is feasible in the majority of patients 
with benign and malignant esophageal disease. A longer duration of SEMS therapy and the 
use of partially covered SEMSs both impeded SEMS removal. Moreover, overlapping SEMSs 
should be avoided for temporary use because stent disintegration and subsequent complica-
tions may occur.
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INTRODuCTION 
In the early 1990s, self-expandable metal stents (SEMSs) were introduced for the palliative 
therapy of esophageal carcinoma. The design of the conventional SEMS aims at restoring 
luminal patency while minimizing the risk of stent migration in patients with a short life 
expectancy.1-3 However, features in the design of the stent that help to prevent migration 
also hamper stent removal once they are in position, particularly after longer periods of time. 
Currently, both fully covered and partially covered SEMSs are used. The covering membrane 
prevents tissue ingrowth and allows sealing of a fistula. In addition, the cover also facilitates 
SEMS removal by preventing embedding of the stent.4 
The ability to remove these stents has opened up new applications, such as the insertion 
of an SEMS as a temporary device in patients with benign esophageal defects or stenosis and 
to bridge chemoradiotherapy in patients with malignant esophageal disease. 5-11 However, 
severe complications during SEMS removal have been reported, but most series reported to 
date are small. 7, 10, 12-15 Hence, this prompted us to evaluate our experience with endoscopic 
SEMS removal in a large cohort of patients with benign and malignant esophageal disease 
and to identify factors associated with SEMS removal outcome.
METHODS
We performed a retrospective analysis from our prospective stent database. Institutional 
review board approval was obtained to publish these results. All patients referred for endo-
scopic SEMS removal for benign and malignant esophageal disease from 2001 to 2010 were 
identified and included in the analysis. Patients with migrated stents were excluded from 
the study. Demographic and clinical data including stent type, stent location, underlying 
disease and stent indication, the technical outcome of stent removal, and procedure-related 
complications were extracted from our database. All patients were followed for at least 6 
months after complete stent removal or until death.
Complications were classified according to the published nomenclature for classification 
of complications.16 Uncomplicated removal was defined as successful removal on the first 
attempt without complications. Complicated primary removal was defined as removal failure 
and/or stent removal with complications on the first attempt.
Stent removal
Stent removal techniques varied according to the type of stent. All procedures were per-
formed with the patient under conscious sedation by using a standard video gastroscope 
(GIF-240, GIF-160, GIF-180, GIF-H180; Olympus Optical Co, Tokyo, Japan). Partially covered 
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SEMSs were removed by grasping the distal edge of the stent with retrieval forceps. The distal 
end of the stent was subsequently inverted, and the stent was removed by gradual traction 
on the distal end leading to complete inversion (Video 1, available online at www.giejournal.
org). Fully covered SEMSs were removed by pulling the proximal retrieval lasso or by grasping 
the proximal metal end of the stent with a polypectomy snare. No overtube or retrieval cap 
was used. Removal of a stent-in-stent was considered a single extraction procedure. After 
stent removal, retrieved SEMSs were carefully examined for completeness, and the esopha-
gus was inspected endoscopically. Patients were admitted overnight for clinical observation 
if no new stent was inserted. A same-day esophagogram with gastrografin was performed 
only in case of clinical or endoscopic suspicion of perforation or persistent fistula. A clear 
liquid diet was first started in the absence of such suspicion to be expanded in the next hours 
in the absence of symptoms suggesting complications.
Statistical analysis
Numerical data are presented as the mean with the standard deviation or median with the 
interquartile range (IQR), as appropriate. The Student t test, chi-square test, and Pearson’s cor-
relation or their nonparametric equivalents, were used when appropriate. A Cox regression 
model was used to explore the effect of the variables on time until complications occurred. 
Statistical analyses were performed with SPSS software, version 17.0 (SPSS Inc, Chicago, Ill). 
Two-sided P values <0.05 were considered significant.
RESulTS
Patient characteristics
A total of 95 patients underwent a total of 124 endoscopic SEMS removals. Fifty-five of 95 
patients (58%) were male; the mean age was 61 years at inclusion (standard deviation 15 
years, range 14–90 years). Baseline patient characteristics are summarized in Table 1. After 
initial SEMS removal, 29 patients (31%) required placement of another stent and subsequent 
repeat extraction. Twenty-four of these 29 patients (83%) with benign and 5 of 29 patients 
(17%) with malignant esophageal disease required stent replacement. The indications for 
stent removal in patients with malignant incurable disease included stent-related complica-
tions, therapy failure, and stent removal before surgery. Three patients (3%) had 2 SEMSs 
in place (stent-in-stent). Eighty-six of 124 temporary SEMSs (69%) were inserted for benign 
esophageal disease (Figure 1A) and 38 (31%) for a malignancy. Fifty SEMSs (40%) were placed 
for stenosis and 74 (60%) were placed for fistulae. SEMSs were partially covered (n=84, 68%) 
(Figure 1B) or fully covered (n=40, 32%). Twenty-seven of 124 SEMSs (22%) were placed across 
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TABLE 1. Baseline characteristics of patients
Age, y, mean ± SD (RANGE) 61 (14-90)
Sex, no. (%)
   Male
   Female
55 (58)
40 (42)
Indication stent removal, no. (%)
   Benign disease
   Stent related complications
   Therapy failure
   Abscess drainage
   Bridge to surgery
71 (57)
20 (16)
22 (18)
2 (2)
9 (7)
Benign esophageal disease, no. (%)
Malignant esophageal disease, no. (%)
86 (69)
38 (31)
Esophageal stenosis, no. (%)
Esophageal fistula, no. (%)
50 (40)
74 (60) 
Duration stent therapy, median (range) 30 (1-587)
A
C
B
D
Figure 1. 
A. Endoscopic view showing a benign esophageal fistula in the distal esophagus. B. Full expansion of the Ultraflex stent and complete sealing 
of the esophageal wall 3 months after stent insertion. Granulomatous tissue growth is visible. C. The distal edge of the uncovered segment is 
graspedwith retrieval forceps. D. Stent breakage occurred as a result of endoscopic traction.
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the gastroesophageal junction. The shaft diameter ranged between 16 and 20 mm. Median 
stent length was 12 cm (IQR 2 cm, range 7-15 cm). Median duration of stent therapy was 30 
days (IQR 26 days, range 0-587 days). Indications for stent removal are summarized in Table 1.
Uncomplicated stent removal
SEMS removal was successful and uncomplicated in 89% (110/124). Median time interval 
(indwelling time) to uncomplicated removal was 28 days (IQR 22 days, range 1 to 393 days). 
Of these, 76 of 110 SEMSs (69%) were inserted for benign esophageal disease and 34 of 110 
SEMSs (31%) for malignant esophageal disease; 71 SEMSs (65%) were partially covered, and 
39 SEMSs (35%) were fully covered. One patient had a stent-in-stent (1%).
Complicated stent  removal
SEMS removal was complicated in 11% (14/124). Median time interval to complicated re-
moval was 126 days (IQR 248, range 14-587). Ten of 14 SEMSs (71%) had been inserted for 
benign disease and 4 SEMSs (19%) for a malignancy; 13 SEMSs (93%) were partially covered 
and 1 (7%) was fully covered. Two patients (18%) had a stent-in-stent. Of the 12 patients in 
whom the primary attempt at stent removal failed, 9 (75%) underwent a second attempt. 
The secondary success rate in these patients was 33%; 4 SEMSs (44%) were removed in 2 to 
7 endoscopic sessions. This brought the overall success rate of endoscopic removal to 96%. 
Surgical removal was deemed necessary in 3 of 124 (2.4%); 2 SEMSs were removed by mini-
gastrotomy to allow endoscopic access for distal antegrade removal because endoscopic 
retrograde removal had failed, and 1 SEMS was removed during radical esophagectomy. In 
the latter patient, the stent had been placed as a bridge to surgery. In 2 patients (1.6%) with 
a malignancy and poor prognosis, the embedded stent was left in place without further at-
tempts at endoscopic removal. 
During 6 removal procedures (4.8%), moderate or severe complications occurred. Five 
stents (4.0%) broke during stent extraction, necessitating multiple endoscopic sessions to 
remove the fragments (Figure 1C,D). In 2 of 5, parts of the broken stent remained embedded 
in the esophageal wall. One of these 2 patients had failed to comply with the original appoint-
ment for timely stent removal and had been lost to follow-up without a permanent residence 
and contact address. He came back 84 weeks after stent placement with dysphagia. Stent 
disruption occurred during stent extraction. A filament migrated over the next 3 years and 
perforated the thoracic vertebrae, which resulted in osteodiscitis and a thoracic empyema. 
This patient, in whom the SEMS had been placed for Boerhaave’s syndrome, required an 
esophageal resection. In the other patient with an irretrievable stent fragment, an esophago-
respiratory fistula developed after an interval of 11 months. In 1 patient, retrieval of the SEMS 
was complicated by a sleeve mucosectomy of the proximal esophagus (Figure 3), resulting in 
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a proximal stenosis. In this patient, removal took place 4 months after SEMS insertion, after 4 
failed attempts elsewhere that had included application of argon plasma coagulation. Minor 
self-limiting postprocedure bleeding occurred during removal of 2 SEMSs (1.6%). 
Stent removal outcome was time dependent; patients with an uncomplicated SEMS ex-
traction had the stent in place for a significantly shorter time compared with patients with 
Figure 2. This figure demonstrates the influence of the duration of stent therapy on the  outcome of stent removal. The gray triangles represent 
fully covered SEMSs and the white triangles partially covered SEMSs. Patients with a failed or complicated stent extraction had the stent in place 
significantly longer compared with patients with an uncomplicated primary stent extraction (126 days vs 28 days; P = .01).
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a complicated SEMS extraction (P=0.006) (Figure 2). We also found significant difference in 
the success rate of stent removal between partially and fully covered SEMSs (85% vs 99%, 
P=0.035) and between 1 versus 2 stents (99% vs 86%, P=0.033). Removals of 4 of 27 SEMSs 
(15%) placed across the gastroesophageal sphincter and 10 of the remaining 97 SEMSs (10%) 
were complicated, which did not reach statistical significance (P=0.50). No clinically significant 
differences were found in the stent removal outcome between benign and malignant disease 
and between fistulae and stenoses. Other variables including stent type, luminal diameter, and 
stent size were also not independently associated with the stent removal outcome (Table 2).
Figure 3. Sleeve mucosectomy complicating partially covered SEMS removal 4 months after insertion.
TABLE 2. Stent removal
Uncomplicated Complicated    P 
No. (%) of stents 110 (89) 14 (11)
2 overlapping stents, no. (%)
1 stent, no. (%)
1 (1)
109 (99)
2  (14)
12 (86)
.033
Partially covered stent, no. (%)
Fully covered stent, no. (%)
71 (65)
39 (35)
13 (13)
1 (3)
.035
Esophageal fistula, no. (%)
Esophageal stenosis, no. (%)
64 (58)
46 (42)
10 (71)
4 (29)
.399
Benign esophageal disease, no. (%)
Malignant esophageal disease, no. (%)
76 (69)
34 (31)
10 (71)
4 (29)
.563
Duration therapy, days, (range) 28 (0 - 393) 131 (14 - 587) 0.006
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DISCuSSION
Covered SEMSs have become the treatment of choice for malignant stenosis and esoph-
agorespiratory fistulae. SEMSs are generally used as palliative treatment for patients with 
a limited life expectancy, with no intention of subsequent stent removal.17 Side effects such 
as ulceration, stricture formation, perforation, and bleeding are well-known complications 
of long-term stent placement.10, 18-21 To avoid these complications, timely removal of SEMSs 
in patients with benign esophageal disease is crucial. Currently, covered SEMSs have been 
increasingly used as a temporary device in patients with benign esophageal perforations or 
stenosis. 8, 10, 22-27 Stents are also successfully used as a bridge to therapy and to maintain oral 
intake before surgery or chemotherapy and radiotherapy.28-29 
Some studies reported unacceptable rates of complications caused by temporary stent 
placement. 14, 30-32 In 1 series using SEMSs for benign indications, half of the patients expe-
rienced a complication. 22 A pooled analysis of 10 studies of self-expandable plastic stent 
placement for benign strictures revealed a major complication rate of 9%, a migration rate of 
24%, and a reintervention rate of 21% in 130 cases.33 A similar analysis of 12 studies evaluating 
SEMSs in 168 cases revealed similar results (complication rate of 10%, migration rate of 14%, 
and an efficacy of <50%).34 Based on these prohibitive rates, some authors have suggested 
that expandable stents should not be inserted temporarily.14, 30-31, 35-36 In the United States, the 
self-expandable plastic Polyflex stent is the only stent currently approved for removal after 
long-term placement. The currently available SEMSs have not received U.S. Food and Drug 
Administration approval for removability. 37 
Severe complications from SEMS removal have also been reported.7, 10, 12-15, 22-23 In a large 
series describing nonsurgical removal of 119 fully covered nitinol stents, Yoon et al reported 
a success rate of 99% and only 1 major complication. The latter, a major bleeding, resulted 
in death. 7 In this study, however, almost one fourth of the stents (23%) had migrated and 
were retrieved from the stomach or proximal esophagus. In a more recent study, Eloubeidi 
and Lopes24 described a series of 22 successful fully covered nitinol stent removals with 1 
stent fracture and no major complications related to the retrieval procedure. Leers et al.38 de-
scribed removal of 26 partially covered stents in a series of 31 patients with esophageal leaks 
and perforations without complications. Similar findings with regard to the safety of stent 
removal after short-term placement have been reported in smaller series.5-6, 39 In our study, 
the largest series of esophageal stent removals to date and the first series describing a variety 
of partially and fully covered SEMSs, 124 esophageal SEMS removals were attempted in 95 
patients at a single institution. Stents that had migrated were excluded from analysis because 
they are mobile and pose a distinct challenge to the endoscopist. All patients were followed 
until complete stent removal; thus, we were able to assess the feasibility and complications 
of this intervention. 
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The uncomplicated primary removal rate was 89%, which is lower than the 97% to 100% 
in previously published series.7, 24, 40 However, this series included both fully and partially 
covered SEMSs, a variety of indications, and indwelling time after insertion. After 1 to 7 en-
doscopic sessions, 96% of all stents were removed endoscopically; 3 stents (2.4%) were surgi-
cally removed and 2 stents (1.6%) were left in place. Successful endoscopic removal was time 
dependent; patients with an uncomplicated primary SEMS extraction had the stent in place 
for a significantly shorter time compared with patients with a complicated or failed SEMS 
extraction. Previously published series reported controversial data on the optimal stenting 
period.8, 10, 22, 30, 41-42 Most series recommend stent removal between 3 and 10 weeks.8, 22, 43 How-
ever, Choi et al. reported successful stent removal even after 8 years.41 Based on our results, 
we advocate removing the SEMSs within 6 weeks after placement in patients in whom stent 
removal is deemed necessary regardless of stent type. In cases of persisting symptoms after 
stent removal, placement of another stent is the preferred approach.10, 37 
An important finding of this study is the significant difference in the success rate of stent 
removal between partially and fully covered SEMSs. This is related to stents becoming 
embedded. Partially covered SEMSs are prone to tissue ingrowth through the uncovered 
mesh.4, 44 In our series, removal of 13 partially covered SEMSs failed because of embedded 
stents. Two previous studies have reported its mechanism: initially, pressure necrosis is 
caused by the radial force of the stent, leading to migration of the struts of the stent into the 
mucosa and submucosa, followed by a chronic lymphocytic inflammatory reaction, mucosal 
hyperplasia, and subsequent fibrosis.45-46 Although tissue ingrowth is beneficial for prevent-
ing stent migration, it makes removal complex and challenging. Jaganmohan and Raju15 
reported that fully covered SEMSs can also become embedded in the esophageal wall; this 
was also encountered in 1 case in our series. It has been suggested that pressure necrosis of 
the ingrown hyperplasic tissue into the uncovered segments can be created by the insertion 
of a self-expandable plastic stent through the SEMS to facilitate SEMS removal.8, 47-50 
Complications occurred in 6% of the SEMS removals. The most commonly encountered 
complication was stent breakage, which occurred as a result of endoscopic traction with 
retrieval forceps in 5 of 124 removals (4%); similar rates have been reported by other groups 
(0%-5%).7, 24, 38, 40, 51-52 Caution should be taken when using overlapping SEMSs as a temporary 
device; 2 patients with SEMS breakage had overlapping stents in place (P<0.05). In case of 
stent breakage and possibly incomplete endoscopic stent removal, careful endoscopic 
evaluation or surgery should be considered to ensure that all broken segments have been 
removed. Broken filaments may migrate and may lead to life-threatening complications such 
as perforation and empyema, which occurred in 2 patients a number of years after SEMS 
removal. 
There are some limitations to the study. First, various endoscopic removal techniques were 
used for a wide range of stents that differed in flexibility, radial force exerted, luminal diam-
eter, and stent material. Multiple endoscopic removal techniques have been described in the 
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literature, including pulling the proximal lasso, distal-to proximal invagination of the stent, 
and the use of an overtube, retrieval hoods, and retrieval hooks. 7-8, 53-54 We used 2 removal 
techniques: the stent inversion technique for a partially covered SEMS and stent retrieval by 
pulling the proximal edge or lasso of the stent with retrieval forceps in a fully covered SEMS. 
No firm conclusions can be drawn regarding the most advantageous removal technique 
or the optimal stent design. The principal limitation of this study is the retrospective and 
nonrandomized design, a shortcoming that was also observed in similar previous studies5, 
11, 24 and that will be unlikely to overcome because it will be difficult to randomize sufficient 
numbers of patients to different extraction techniques. 
In conclusion, this study shows that endoscopic removal of partially and fully covered SEMSs 
is feasible in the majority of patients with benign and malignant esophageal disease and pro-
vides a basis for using SEMSs as a short-term treatment, but with a considerable amount of 
caution. Both a longer period of stent placement and the use of partially covered SEMSs are 
associated with a negative effect on stent removal outcome. Moreover, overlapping SEMSs 
should be avoided for temporary use because stent disintegration and subsequent devastat-
ing complications may occur. These findings do not provide firm guidance on the optimum 
choice of temporary SEMSs in relation to indwelling time. We know that partially covered 
SEMSs are less likely to migrate but are more difficult to remove and that fully covered SEMSs 
have a higher migration rate but are easier to remove. Current prospective comparative trials 
will certainly shed more light on this issue and may provide a more differentiated view on 
optimal timing of SEMS extraction in relation to stent type.
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AbSTRACT
Objectives: The standard approach to benign esophageal perforations consists of conserva-
tive treatment or surgery. In this study, we investigated the efficacy of short-term stent place-
ment for nonmalignant esophageal perforations.
Methods: This is a prospective single-center study of patients with benign esophageal perfo-
rations in whom a removable self-expandable stent was placed. Data were collected from a 
prospective database, endoscopy records, and operation reports. To obtain follow-up data, 
we contacted the patients, their relatives, or their general practitioner.
Results: A total of 33 patients underwent stent insertion owing to an iatrogenic perforation 
(n = 19), Boerhaave’s syndrome (n = 10), or other causes (n = 4); this resulted in an immediate 
and complete sealing of the lesion in 32 patients (97%). Stents migrated in 11 patients (33%). 
Four patients required an esophageal resection for failed stent therapy (n = 3) and failed stent 
removal (n = 1). The 90-day mortality rate was 15% . A total of 33 endoscopic stent extractions 
were attempted. Overall, 23 stents were extracted within 6 weeks (group I) and 10 stents 
between 6 and 84 weeks (group II). Extractions were uncomplicated in all patients in group 
I (100%) vs. in 5 patients in group II (50%) (P = 0.001). Six extraction-related complications 
occurred in group II, including two self-limiting bleedings, three stent fractures, and one 
impacted stent.
Conclusions: In patients with a benign esophageal perforation, temporary stent therapy is 
effective and provides a good alternative to surgery. Complications due to stent removal can 
be prevented by removal of the prosthesis within 6 weeks after insertion, without compro-
mising the efficacy of treatment.
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INTRODuCTION
Benign esophageal perforation is a life-threatening condition that requires early recogni-
tion and aggressive management. The mortality rate of esophageal perforation is reported 
to be as high as a 100% when left untreated.1 A small subset of patients can be treated 
conservatively with nil per mouth and pleural drainage. Surgical treatment options include 
esophageal repair and esophagectomy; the mortality rate after surgery is in the range of 
12-50%.2-5 Over the past few years, good results for the management of benign esophageal 
perforations have been reported by temporary deployment of a covered self-expandable 
stent to firmly seal the lesion.6-9 Indications included iatrogenic perforations after dilation of 
caustic lesions, anastomotic leaks after surgery, and lesions due to Boerhaave’s syndrome.10-12 
Although stent placement is a minimally invasive procedure,13-15 stent therapy is associated 
with severe complications, including haemorrhage, incomplete sealing, perforation, and 
stent migration.16-17 Furthermore, even though some of the newer stents are labeled as being 
removable, extraction can be complex due to embedding of the endoprostheses into the 
mucosal wall.6 The optimal duration of stent therapy has not been established.6,18 The aim of 
this study was to evaluate the outcome of temporary esophageal stenting in the manage-
ment of benign perforations.
METHODS
This prospective cohort study was conducted in a large tertiary referral center. From 2001 
to 2008, all patients with benign esophageal perforations referred to the Departments of 
Gastroenterology and Hepatology at the Erasmus MC were included. Demographic data 
such as age, gender, and cause of esophageal perforation were retrieved from a prospective 
database. Clinical data such as location and size of the lesion, stent type and the techni-
cal outcome of stent insertion were retrieved from endoscopy records. Follow-up data on 
complications, re-interventions and survival were retrieved from electronic hospital records, 
including endoscopy and operation reports. In case of missing follow-up information, we 
contacted the patients, their relatives, or their general practitioner.
Stent placement was performed under endoscopic and fluoroscopic control, according to 
manufacturer’s directions and standard protocol.19 Immediately after the procedure a small 
amount of clear liquid was administered by mouth to evaluate passage, retrosternal pain, 
and aspiration. Pleural cavities were drained with thoracostomy drains. Broadspectrum an-
tibiotics were administered intravenously. Technical success was defined as successful stent 
deployment at the required position with no evidence for persistent leakage under contrast 
fluoroscopy. Stent dysfunction was classified as either incomplete sealing of the esophageal 
leak, stent migration, or dysphagia due to stent obstruction. Therapy failure was defined as 
Chapter 7
96
persistent leakage during stent therapy or after stent extraction. Complications were defined 
as either mild or severe according to published criteria.19 Severe complications included 
perforation, fistula, aspiration pneumonia and hemorrhage. Mild complications included 
retrosternal pain or symptomatic gastro-esophageal reflux. Patients were classified into two 
groups, namely short-term stenting (group I) and long-term stenting (group II). Short-term 
stenting was defined as stent therapy for < 6 weeks, and long-term stenting was defined as 
stent therapy for ≥ 6.20
 
Stent extraction
Stent removal techniques varied somewhat according to the type of stent. The Ulatraflex 
stent®(Boston Scientific, Natick, MA) and Hanarostent® (M.I. Tech, Seoul, Korea) were extracted 
most frequently. Ultraflex stents were generally removed by grasping their distal edge with 
a forceps and pulling the stent inside out. Hanarostents were removed by using the retrieval 
lasso located on the proximal end of the stent.
Statistical analysis
Numerical data were described using mean with s.d. or median with interquartile range, as 
appropriate. Cox regression analysis was used to evaluate the effect age, cause of the perfora-
tion, and the time interval to stent therapy on treatment outcome. The Kaplan-Meier method 
was used to calculate survival from the date of stent insertion to the date of death, and if 
patients were still alive to January 1, 2009. Statistical analyses were conducted using SPSS 
software (SPSS 15.0, Chicago, IL). Two-sided P values < 0.05 were considered significant.
RESulTS
Patient characteristics
Between 2001 and 2009, 33 patients underwent esophageal stent insertion for a benign 
perforation. In this cohort, 50 esophageal stents were inserted: 45 self-expandable metal 
stents (SEMSs) (90%) and 5 self-expandable plastic stents (10%). In all, 38 of these stents were 
partially covered (76%) and 12 were fully covered (24%) (Table 1). Baseline patient charac-
teristics are summarized in Table 2 . The mean age at stent insertion was 57 years (range 
13 – 87 years). The majority of perforations were iatrogenic (n = 19) (Figure 1). Other causes 
included Boerhaave’s syndrome (n = 10), foreign body ingestion (n = 1), trauma (n = 1), and 
97
Short-term esophageal stenting in the management of benign perforations
Chapter 7
anastomotic leakage after surgery (n = 2). Overall, 14 patients (42%) required a stent in the 
proximal or mid-thoracic esophagus, 19 patients (58%) in the distal esophagus. A
computed tomography scan was performed in 12 of 33 patients (36%) before stent insertion. 
In all 12 patients, mediastinal air and pleural effusions were observed on the scan. One of 12 
patients (3%) had a thoracic abscess.
Stent therapy
Stent insertion was technically feasible in all patients (100%); all stents showed adequate 
deployment after release (Figure 2). The median time interval between the perforation and 
stent insertion was 1 day (range 0 – 14 days). Initial stent insertion resulted in an immediate 
and complete sealing of the esophageal wall in all but one patient (97%). The latter patient 
with Boerhaave’s syndrome had a very large leak, which was insufficiently covered by the 
stent and underwent an esophageal resection 1 day after stent placement. Before stent 
placement, this patient had been considered by the surgeon as ineligible for repair. Two 
patients developed secondary leakage within 1 week despite an in situ stent. Both patients 
also underwent subsequent esophageal resection. Together, these three patients (9%) with 
TABLE 1. Stent types
n (%)
FerX-Ella stent (Ella-CS, Hradek Kralove, Czeck Republic) 1 (2)
Flamingo Wallstent (Boston Scientifi c, Natick, MA) 3 (6)
Polyflex stent (Rüsch AG, Kernen, Germany) 5 (10)
Hanarostent (M.I. Tech, Seoul, Korea) 6 (12)
Ultraflex stent (Boston Scientifi c, Natick, MA) 35 (70)
TABLE 2. Baseline characteristics of patients
Age, y, mean ± SD (RANGE)  57 ± 18 (13-87)
Sex, no. (%)   
   Male  
  Female
22 (67)
11 (33)
Etiology, no. (%)
   Iatrogenic lesion
   Boerhaave’s syndrome
   Anastomotic leakage
   Trauma
   Foreign body ingestion
19 (58)
10 (30)
2 (6) 
1 (3) 
1 (3)
Location lesion, no. (%)
   Proximal / mid-esophagus
    Distal esophagus
14 (42)
19 (58)
Initial stent type, no. (%)
   Partially covered
   Fully covered
30 (91)
3 (9)
Stent size, cm, mean ± SD (range) 12 ± 1 (9-14) 
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therapy failure were the only patients treated with esophageal resection; no patients were 
treated with surgical esophageal repair. During further follow-up, 12 of the 33 patients (36%) 
required a total of 17 additional stents because of recurrent leakage, while the stent was in 
situ (n = 4) or following stent migration (n = 4), development of a second esophageal wall 
perforation (n = 1), or recurrent leakage after stent extraction (n = 8). Stent migration was 
managed by stent repositioning (n = 4), stent removal (n = 1), additional stent insertion (n 
= 4), or no intervention as the stent evacuated spontaneously and the perforation site had 
closed (n = 2).
Additional therapy
All patients received broad-spectrum antibiotics intravenously. In all, 5 of 33 patients (15%) 
underwent surgical debridement of a pleural empyema, and all patients underwent percuta-
neous drainage of the pleural cavity.
Outcome
In all, 7 of our 33 patients (21%) died, 5 of them within 90 days after stent insertion. Overall, 
4 of 33 patients died from progressive multiple organ failure due to uncontrollable sepsis, 1 
died after developing multiple spontaneous gastrointestinal perforations as part of a crest 
syndrome, 1 died due to complications after esophageal resection, and 1 died after gastric 
surgery. In this limited series, the overall mortality rate was not associated with age, gender, 
cause of the perforation, or the time interval to stent therapy. A total of 26 patients (79%) 
survived. Three of them had undergone esophagectomy with stent removal during surgery. 
Figure 1. Endoscopic view showing an iatrogenic perforation marked 
with two clips in the distal esophagus.
Figure 2. Endoscopic view after stent insertion, showing full 
expansion of the stent and complete sealing of the esophageal wall.
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In the remaining 23 patients, successful closure of the esophageal defect had been achieved 
with stent therapy. Closure was confirmed after a median duration of 6 weeks after initial 
stent insertion (range 1 – 102 weeks) (Figure 3). All these 23 patients underwent endoscopic 
stent extraction with a total of 33 stents being removed after a median of 5 weeks after stent 
insertion (range 1 – 84 weeks). A total of 23 stent extractions were performed within 6 weeks 
after stent insertion (group I). In all, 10 stent extraction procedures were performed after 
6 – 84 weeks (group II) (Table 3). One patient in group I (4%), vs. three patients in group II 
(30%) had multiple stents in place (NS). All 23 stent extractions were successful and without 
complications in group I (100%) (Figure 4), vs. 5 of 10 stent extractions in group II (50%) (P = 
0.001). During stent extraction in group II; six complications occurred in five patients includ-
ing two self-limiting bleedings, three stent fractures, and one stent impacted on endoscopic 
retrieval. In the latter patient, a surgical mini-gastrotomy was performed to remove the stent. 
Two of three patients with a broken stent had a complete endoscopic stent removal each 
after three attempts. The third patient refused further treatment after initial stent insertion. 
This patient presented with dysphagia 84 weeks later at which time stent disruption occurred 
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Figure 3. Successful closure of the esophageal defect vs. time after 
stent insertion in 23 patients.
Figure 4. Endoscopic view after stent extraction. The former 
perforation is entirely closed. Granulomatous tissue growth is visible.
TABLE 3. Stent extraction
Complicated Uncomplicated
Number of extractions 5 28
Stents  
   Partially covered
   Fully covered
   Stent – in – Stent 
3
0
2
23
3
2 
Time interval 
    < 6 weeks
    ≥ 6 weeks 
0
5
23
5
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during stent extraction. The stent was still incompletely removed after nine attempts. This 
patient subsequently developed a stenosis with a thoracic empyema and finally required an 
esophagectomy. At surgery, it was found that a strand from the stent had perforated a tho-
racic vertebrae. After a median follow-up of 2 years, none of the surviving patients reported 
stent-related dysphagia or other long-term side effects.
DISCuSSION
Stent placement is the standard treatment in patients with a malignant esophageal perfora-
tion. 6,21  The primary goal of this therapy is to immediately seal the esophageal perforation to 
prevent further leakage.9 Until recently, stent insertion was not considered in the treatment 
of benign esophageal perforations, mainly because available stents could not be removed. 
Some newly designed stents are more easily extractable and have been used for the treat-
ment of nonmalignant esophageal disease.8-9,22-23 Thus far, this application is limited because 
of serious concerns regarding the long-term complications and hitches relating to stent 
extraction.24-25
Despite these concerns, stent placement was in recent years the treatment of first choice 
for all patients with a benign esophageal perforation referred to our unit. This occurred ir-
respective of the underlying condition. The exceptions were patients with perforations of 
the cervical esophagus and anastomotic leaks after esophageal resection. They were mostly 
treated conservatively or by surgical deviation and subsequent repair; only two patients with 
anastomotic leaks were considered for stenting and were included in this study. For any other 
condition, such as Boerhaave’s syndrome and iatrogenic perforation, all patients underwent 
stenting with the exception of 5 of 15 patients with Boerhaave’s syndrome. These patients 
were primarily referred to the surgery unit. The evaluation for surgery was performed by the 
collaborative team of surgeons and gastroenterologists. 
The proportion of perforations directly sealed after use of a covered stent in malignant 
fistula is in the range of 90 – 100%.6,9,26 Our series corresponds with these success rates; in 
32 of 33 patients (97%), the lesion was directly sealed after stent insertion. One patient with 
Boerhaave’s syndrome had a very large esophageal tear, which was insufficiently covered 
by the stent and which before stent placement had been considered by the surgeon as 
ineligible for repair. Two patients developed secondary leakage within 1 week, and therefore 
these patients required surgery. Direct referral to surgery would have spared these patients 
the burden of endoscopy with stent placement. These patients did not differ with respect 
to relevant baseline details such as location, size, and duration of the perforation with other 
patients in whom stent therapy proved to be successful, and who were thus spared the bur-
den of surgery. In this balance, with a good success rate of stenting as therapy with fewer 
morbidity and mortality rates than in published surgical series, we consider it relevant to 
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offer patients with benign esophageal perforation stent therapy as first treatment option, 
irrespective of the underlying condition.2-5 Further series have to increase our knowledge on 
patient selection, optimal stent designs, and treatment protocols for this indication. 
In accordance with smaller series, the most common cause of therapy failure was stent 
migration (33%).27 This migration rate is high compared with the migration rate in malignant 
stenosis, but this is conceivable because of the absence of a stenosis securing the stent posi-
tion.28-29 In all cases, stent migration was successfully managed by either stent replacement 
or stent repositioning. 
There are no accepted criteria with regard to the optimal duration of stent therapy. Ideally, 
a single stent would have to seal the esophageal wall defect, permit normal food intake, 
allow the esophageal wall to heal, and be easy to extract, thereby minimizing the number of 
complications while preserving the esophagus. With regard to the duration of stent therapy, 
this poses conflicting demands. In a normal esophagus, healing of the esophageal wall may 
take several weeks to months. Fischer et al. experienced successful esophageal healing and 
stent removal within average of 4 weeks after insertion, and in another case report, a stent was 
retrieved uneventfully after 8 months.8,18 Nevertheless, severe complications after long-stay 
stent insertion have been documented in a number of reports, including the development 
of an epidural abscess and an aorta- esophageal fistula.30-31 Cwikiel et al. placed nitinol stents 
in healthy pigs and observed significant inflammatory change with degeneration of the 
muscular layer, 1 – 8 weeks after insertion. After a prolonged stenting period, the deeper wall 
layers also became affected. In the same article, the authors observed the same phenomenon 
in patients with benign stenoses treated by a nitinol stent when removed after 4 – 7.5 months 
after insertion. After 7.5 months, the stent was deeply embedded into the wall and this 
patient required an esophageal resection.32 Two studies reported severe secondary obstruc-
tion requiring esophagectomy after long-term stenting.25,33 In our series, we observed one 
stent-induced stricture in a patient with a stent in place for 84 weeks. Stents were retrieved 
endoscopically after a median of 5 weeks after stent insertion (range 1 – 84 weeks). Complete 
closure of the defect was observed in 23 of 33 patients (70%) at a median of 6 weeks after 
initial treatment (range 1 – 102 weeks). All stent extractions within 6 weeks after insertion 
were uneventful. Importantly, this study shows a considerable rate of serious complications 
in those cases in which stents were extracted after  ≥ 6 weeks after stent insertion. In all, 10 
stents were in place for ≥ 6 weeks (range 6 – 84 weeks) and all were firmly embedded into 
the esophageal mucosa. Extraction resulted in six major complications. These observations 
should caution clinicians to leave stents in for a prolonged period of time, although it should 
be noted that the two groups were not similar with regard to the disease characteristics and 
the number of stents inserted. In the prolonged stenting group, three patients had two stents 
in place. Given the small number of cases, it remains speculative whether this is indeed as-
sociated with specific introduction or stent removal problems. 
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On the basis of these results, no firm guidelines with regard to optimum choice of stent 
type can be given for this indication, given the limited number of patients and the wide va-
riety of SEMSs used. Overall therapeutic outcome depends both on successful sealing of the 
wall defect and the success of subsequent SEMS removal. As both fully and partially covered 
SEMSs differ in both respects, a comparative study is currently being performed in our institu-
tion. Self-expandable plastic stents have been described to provide an alternative for SEMSs 
in the treatment benign esophageal disease, mainly for the ease of stent extraction.7,34-36 Re-
portedly, however, plastic stents are associated with a higher migration rate and furthermore, 
they require being loaded onto the significantly larger and stiffer delivery device. In stenotic 
disease, plastic stent insertion requires more commonly previous dilation compared with the 
use of SEMSs.37-38 In a recent study, 40 patients underwent plastic stent placement for benign 
esophageal stenosis, 22 serious complications occurred including one death, and the success 
rate of stenting was only 40%.36 In our series, five plastic stents were used. In none of these any 
complications occurred. Despite the use of stent therapy, antibiotics and thoracic drainage, a 
total of seven of our patients died as a result of esophageal perforation or underlying disease. 
All these patients were deemed unfit for surgery leaving stent insertion and supportive care 
as the only option. The degree of mediastinal sepsis as seen on computed tomography scan 
before stent insertion was not predictive for progressive sepsis. The time interval between 
the perforation and treatment may be of critical importance for the outcome of the therapy. 
Three reports in the literature have suggested that an increased delay worsens the patients’ 
prognosis.5,9,39 From our data, we cannot extract such correlation. In fact, this study confirms 
that even in long-standing perforations, those who would otherwise undergo esophageal 
resection can still be good candidates for stent treatment. 
In conclusion, temporary endoscopic placement of a stent is safe and effective in patients 
with a benign esophageal perforation. Although preservation of the esophagus is secondary 
to survival, this study shows that the esophagus can be preserved in the majority of patients. 
The migration rate is high; however, this can be effectively managed by stent repositioning 
or placement of a second stent. Complications due to stent removal can be prevented by 
removal of the stent within 6 weeks after insertion.
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AbSTRACT
Background and study aims: Self-expandable metal stent (SEMS) therapy has become a good 
alternative to surgery for patients with non-malignant fistula and stenosis of the esophagus. 
A major drawback of the current available stents is their migration tendency. Stent design 
features that help to prevent migration such as the type of covering, also hamper stent 
removal. We performed this trial to compare partially-covered SEMS (pcSEMS) with fully-
covered SEMS (fcSEMS) in patients with non-malignant esophageal disease.
Patients and methods: Patients with non-malignant esophageal disease with an indication 
for temporary SEMS placement were randomly assigned to fcSEMS or pcSEMS placement. 
SEMS removal was scheduled 4 weeks post-SEMS insertion.
Results: Forty-four patients (M/F 34/10, mean age 66; range 21 - 83 years) were random-
ized, 32 had a esophageal perforation or fistula, and 12 had a non-malignant esophageal 
stenosis. They were treated with a total of 22 pcSEMS and 22 fcSEMS. Functional success was 
achieved in 43 (98%) patients; pcSEMS therapy failed in one patient due to ineffective sealing 
of the perforation. Stent migration occurred in 4 (18%) patients with a pcSEMS, and in 8 (36%) 
patients with a fcSEMS (p=0.21). Two (5%) patients died due to infectious complications of 
the perforation. One (2%) patient had progression of underlying disease impeding further 
intervention or stent removal. A total of 41 SEMS were successfully removed; 21 pcSEMS were 
removed after a median duration of 29 days, and 20 fcSEMS after 27 days. Two (9%) severe 
complications occurred during pcSEMS removal, and no complications occurred during 
fcSEMS removal (p=0.24). 
Conclusions: Both fcSEMS and pcSEMS are equally effective for the treatment of non-ma-
lignant esophageal disease, in particular sealing of non-malignant esophageal wall defects 
and restoring luminal patency. Migration is fairly common with both types of stents. Since 
removal of pcSEMS is considerably more complex than removal of fcSEMS, we advocate the 
use of fully covered stents for non-malignant esophageal disease.
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INTRODuCTION
Self-expandable metal stents (SEMS) are increasingly used in non-malignant esophageal dis-
ease as minimally invasive alternative to surgery. SEMS can effectively restore luminal patency 
in patients with esophageal strictures, and are also an effective treatment for esophageal 
fistulae or perforations.1-2 In a recent study, we reported the outcome of temporary SEMS 
placement in 33 patients with a non-malignant esophageal fistulae and perforations.3 In this 
study we were able to seal various leaks and fistulae in 97% of cases. The 90-day mortality 
rate was 15%, which is less than previous surgical series. 
SEMS were originally designed for use in patients in whom no other treatment options were 
available, in particular patients with locally advanced or metastatic cancer. To prevent migration 
most SEMS are partly uncovered. The uncovered part of the stent rapidly embeds in the mucosa, 
thus firmly anchoring the stent to the wall. It was thought that this would make stent removal 
difficult and hazardous. However, further experience showed that stent placement was feasible, 
in particular when performed within 6 weeks after stent placement.3-4 SEMS therapy has now 
become a good alternative to surgery for patients with non-malignant fistula and stenosis of 
the esophagus, however it is also associated with risks and procedure-related mortality has 
been reported.1, 5-8 These are in particular related to stent migration and mucosal ingrowth. 
For this reason, different stent designs are being considered. The risk of mucosal ingrowth and 
subsequent stent removal failure can theoretically be reduced by the use of fully-covered stents. A 
major drawback of these stents is their risk of migration, especially in the absence of a stricture, as is 
often the case in non-malignant esophageal perforation or fistula. Stent design features that help 
to prevent migration generally hamper stent removal. This holds especially for partial covering of 
the endoprosthesis. To date no randomized comparative studies have been published on stent 
therapy for non-malignant esophageal disease. In this prospective randomized study, we aimed 
to compare fully-covered SEMS (fcSEMS) and partially-covered SEMS (pcSEMS) for this indication. 
METHODS
Study design and patients
This randomised controlled open trial was conducted at the Erasmus University Medical 
Center, Rotterdam the Netherlands. Patients were eligible for inclusion when they had non-
malignant esophageal perforation or fistula, or stenosis, with an indication for temporary 
stent therapy. Patients were ineligible for the trial if they presented with lesions within 4 cm 
from the upper esophageal sphincter, or with lesions larger than 9 cm, or with active bleed-
ing at endoscopy. The study was approved by the Institutional Review Board of the Erasmus 
MC. All patients provided written informed consent before enrolment.
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Randomisation  
Patients were randomly assigned (1:1) to placement of a partially-covered stent (Ultraflex 
stent®, Boston Scientific, Natick, MA USA) or a fully-covered stent (Hanarostent®, MI tech, 
Seoul South-Korea) (Figure 1). Randomisation was done by computer-generated blocks of 10. 
The randomisation procedure was stratified for two disease groups; perforation/fistulae and 
stenosis. The investigator performing the stent placement and stent removal procedures (JH) 
was by definition unblinded. Patients and the independent investigator evaluating outcome 
measures were blinded to the type of procedure. All authors had full access to all the data in 
the study and had shared responsibility for the decision to submit the report for publication.
Stent characteristics
Patients randomized to pcSEMS were treated with an Ultraflex stent, which consists of a 
partially covered knitted nitinol wire tube. The cover consists of a polyurethane layer that 
covers the midsection of the stent extending to 1.5 cm of each end. The stent is available in 
3 lengths: 100 mm, 120 mm and 150 mm. The stent has a proximal flare with a size of 28 mm, 
and a diameter of 23 mm. Patients randomized to fcSEMS were treated with an Hanarostent, 
which consists of a series of segments of graduated polyurethane-covered 0,4-mm stainless 
steel wire in a cylindrical zigzag fashion segments interspersed with 3-mm sections consist-
Figure 1. Two stent types used in the present study, on the left side the partially covered Ultraflex stent, on the right site the fully covered Hanarostent.
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ing of polyurethane only. This stent is available in 4 lengths: 80 mm, 110 mm, 140 mm and 
170 mm. The stent has a proximal and distal flare of 26 mm and a diameter of 20 mm. 
Insertion procedure
All procedures were performed under conscious sedation using midazolam. The lesion was 
located, inspected and measured with a flexible video endoscope (Olympus Q and 1T series). 
The distances from the dental incisors and to proximal and distal borders of the lesion were 
measured. Stent length was based on the length of the lesion; the stent length was chosen 
at least 3 cm longer than the lesion length, to allow for complete coverage with the stent 
coating and deployment of the flanges above and below the proximal and distal lesion mar-
gins. All stents were positioned over a guidewire and deployed under fluoroscopy or direct 
endoscopic view. One hour after the procedure patients were given a small amount of clear 
liquid by mouth to evaluate passage, retrosternal pain and esophago-respiratory leakage. 
Resumption of oral intake was permitted on the day of SEMS placement.
Removal procedure
Patients were scheduled to undergo stent removal 28 days post-SEMS insertion. The distance 
from incisor teeth to the upper edge of the stent was carefully measured prior to stent re-
moval. Partially covered Ultraflex stents were removed by grasping the distal edge of the 
stent from inside the endoprosthesis with a retrieval forceps. The distal end of the stent was 
subsequently inverted and removed, as has been described previously.4 Hanarostents were 
removed by pulling the proximal retrieval lasso. No overtube or retrieval cap was used. After 
stent removal, the SEMS was carefully examined for completeness and the esophagus was in-
spected endoscopically. Patients were admitted overnight for clinical observation. A contrast 
swallow study with watery contrast was performed on the same-day only in case of clinical 
or endoscopic suspicion of perforation or persistent fistula. A clear liquid diet was started in 
the absence of such suspicion.
Follow-up
Patients were interviewed at the day of stent removal and by telephone four weeks after 
stent removal by one of the authors (NVH) using a protocol-approved questionnaire. In case 
of complications or stent dysfunction, patients were seen for re-evaluation. Patients were 
followed to the end-point, being either stent dysfunction requiring re-intervention, 4 weeks 
post stent removal, or patient death.
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Outcome parameters
The primary outcome for this study was the symptomatic stent migration rate. Secondary 
outcomes included the technical success, functional success, stent position change, pro-
cedural complications, 30-day mortality rate and removal success rate. Symptomatic stent 
migration was defined as a >2 cm change in the distance between the upper incisors and 
the proximal end of the device. Technical success was defined as stent deployment at the 
required position. Functional success was defined as relief of dysphagia, respectively fistula 
sealing. Stent position change was defined as a change of more than 2 cm in the position of 
the proximal flange at removal not causing recurrent symptoms. The dysphagia grade was 
assessed according to the Atkinson’s dysphagia score as follows: 0 = no dysphagia; 1 = ability 
to swallow some solid foods; 2 = ability to swallow semisolid foods; 3 = ability to swallow 
liquids only; and 4 = complete dysphagia.9 Complications were classified as major or minor 
according to published criteria.10 Stent removal rate was defined as the rate of complete 
endoscopic stent removal in a single session. 
Statistical analysis
A previous study showed a 5% migration rate for pcSEMS, which is nearly 40% less than the 
reported migration rate of fcSEMS.11-14 With a 5% type I error with 80% statistical power, the 
required number of patients in each group was determined to be 20 to be able to demonstrate 
a 40% difference in migration rate between treatments. Data were analyzed on an intention 
to treat basis. For comparison of baseline characteristics, differences in continuous variables 
were analyzed by t tests, and differences in categorical variables by χ² tests. Complications 
and recurrent dysphagia or leakage in the two groups were compared with Kaplan-Meier and 
log-rank tests to adjust for time of occurrence of the event and survival differences. Survival 
of the two groups was calculated and compared using Kaplan-Meier curves and log-rank 
test. A two-sided P value < 0.05 was considered statistically significant. All analyses were 
conducted using the Statistical Package for the Social Sciences (SPSS® version 17; IBM, USA). 
RESulTS
Patient characteristics
Of the 46 patients screened for eligibility, 44 patients were included and treated between 
June, 2008 and June, 2010. All patients were followed to the study endpoints, and none was 
lost to follow-up (Figure 2). Twenty-two (50%) patients were assigned to the partially-covered 
Ultraflex stent and 22 (50%) to the fully-covered Hanarostent. Table 1 shows the baseline 
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characteristics for the two groups. Study groups were similar in terms of all baseline clinical 
and procedural characteristics. On inclusion, 32 (73%) patients presented with esophageal 
leaks, and 12 (27%) patients with dysphagia due to a non-malignant stenosis. Esophageal 
leaks included iatrogenic perforations (n=14, 32%), surgical anastomotic leaks (n=11, 25%), 
Boerhaave’s syndrome (n=6, 14%), and fistula of unknown origin (n=1, 2%). In this group, 17 
(53%) pcSEMS and 15 (47%) fcSEMS were inserted. Esophageal stenosis included anastomotic 
strictures after surgery (n=3, 7%), treatment-refractory achalasia (n=3, 7%), radiation stric-
tures (n=3, 7%), post-EMR strictures (n=1, 2%) and strictures of unknown origin (n=2, 5%). In 
this group, 5 (42%) pcSEMS and 7 (58%) fcSEMS were inserted. Median Atkinson dysphagia 
score in both groups was 3 on inclusion. 
Table 1: Baseline characteristics
Ultraflex stent (n=22) Hanarostent (n=22)
Age (years, mean (SD)) 65 (10) 66 (16)
Men/women 16 / 6 18 / 4
Lesion location from incisor teeth (cm, mean (SD) 30 (8) 28 (8)
Length stent (cm, mean (SD) 11 (2) 11 (4)
Indications for SEMS treatment
Perforation Stenosis
17 (77)
5 (23)
15 (68)
7 (32)
Dysphagia score before treatment (mean (SD) 3 (0.4) 3 (0.4)
Data are numbers (%) unless otherwise specified 
Assessed for eligibility (n=46) 
Excluded (n=2) 
•    Not meeting inclusion criteria (n=2) 
Randomised (n=44) 
Allocated to Ultraflex stent placement (n=22) 
•  Received allocated intervention (n=22) 
Allocated to Hanarostent placement (n=22) 
•  Received allocated intervention (n=22) 
Lost to follow-up at 1 month (n=0) 
Lost to follow-up at 2 months (n=0) 
Lost to follow-up at 1 month (n=0) 
Lost to follow-up at 2 months (n=0) 
Analyzed (n=22) Analyzed (n=22) 
Figure 2: Enrolment, randomisation, and follow-up of study patients 
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Stent therapy
Initial stent insertion was technically successful in all patients (100%) and no procedure- 
related complications occurred. Symptomatic SEMS migration occurred in 4 (18%) patients 
with a pcSEMS, and in 8 (36%) patients with a fcSEMS (p=0.21). SEMS migration caused recur-
rent symptoms of leakage in 8 (18%) patients, and recurrent dysphagia in 4 (9%) patients, af-
ter a median of 4 days post-SEMS insertion. These patients were all managed endoscopically 
by stent repositioning (n=4, 9%), stent replacement (n=5, 11%), or stent removal (n=3, 7%). 
Functional success was achieved in 43 (98%) patients; pcSEMS therapy failed in one patient 
due to ineffective sealing. In this patient SEMS removal was performed within 24 hours after 
implantation. Stent position change occurred significantly less often in pcSEMS (n=6) than 
fcSEMS (n=14) (p=0.015).
SEMS removal and follow up
Two (5%) patients with an esophageal leak died during SEMS therapy because of infectious 
complications despite administration of broad spectrum antibiotics, 12 and 30 days after 
OUTCOMES OF STENT THERAPY
Patients n = 44
Ultraflex stent 
n =22 
Hanarostent
n =22
Dysfunction
ff l
Success Dysfunction Success 
Ine ective sea ing n=1
SEMS migration n=4
Severe pain n=1
n=16 SEMS migration n=8
Severe pain n=2
n=12
<4 weeks removal
n=5
4 weeks removal
n=16
No removal:
Patient death n=1
No removal:
Patient death n=1
Disease n=1
4 weeks removal
n=12
<4 weeks removal
n=8 
Complications 
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Figure 3. Outcomes of SEMS therapy
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stent placement. One (2%) patient with a benign esophageal perforation had progression of 
underlying disease impeding further intervention or stent removal. 
A total of 41 SEMS were successfully removed; 21 pcSEMS were removed after a median du-
ration of 29 days, and 20 fcSEMS after 27 days (Figure 3). On follow-up, the median dysphagia 
score was 3. Dysphagia improved at 28 days post SEMS removal in 3 out of 12 (25%) patients, 
only 1 (8%) patient remained symptom free. The degree of improvement was not different 
among the 2 groups. Within 1 month after SEMS removal, 23 (52%) patients received addi-
tional therapy to manage persistent leakage (n=17, 39%), or recurrent dysphagia (n=6, 14%). 
Complications
A total of 5 complications occurred related to SEMS therapy, all consisting of pain following 
placement. There was no significant difference in complication rate between patients treated 
with pcSEMS (n=2, 9%), versus fcSEMS (n=3, 14%) (p=0.33). In 2 (5%) patients pain was man-
aged by the administration of oral analgesics. In 3 (7%) patients, endoscopic stent removal 
was required. Stent-related pain was observed in none of 32 patients with esophageal fistula, 
versus 5 of 12 patients with strictures (p < 0.001). 
Figure 4. Partially covered SEMS removal resulted in mucosal damage and severe stenosis after healing, requiring repeated dilation
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Two (9%) severe complications occurred during pcSEMS removal, and no complications oc-
curred during fcSEMS removal (p=0.24). In one patient, stent breakage occurred on removal. 
This stent was completely removed in 2 endoscopic sessions. After one pcSEMS removal, a 
narrow stenosis developed requiring repeated dilation (Figure 4). Variables including stent 
type, stenosis or fistula, stent location and size were not independently associated with the 
development of major complications, recurrent dysphagia/leakage, or survival. Similar results 
were obtained when the variables were entered into a multivariate Cox regression model.
DISCuSSION
This randomized controlled trial in patients with benign esophageal stenosis and esophageal 
fistulae compared the partially-covered Ultraflex® stent with the newly designed fully-covered 
Hanarostent®. SEMS migration and subsequent relapse of fistulae or dysphagia occurred more 
often in fcSEMS than in pcSEMS, however this difference was not statistically significant. A 
change in the position of the stent, not giving rise to recurrence of symptoms and therefore not 
considered clinically relevant, occurred significantly more often in fcSEMS. Stent placement was 
successful in all patients in both study arms, and stents were equally effective in restoring lu-
minal patency and sealing esophagorespiratory fistulae. Generally SEMS were poorly tolerated 
in patients with benign refractory strictures and long-term clinical results were unsatisfactory. 
In contrast, results of SEMS placement in esophageal leaks were positive. In spite of removal 
within one month after insertion, pcSEMS removal resulted in severe complications in 9%. 
In recent years, a multitude of studies have shown that temporary stent placement is 
effective in patients with benign esophageal disease.1, 15 With the deployment of a self-
expandable stent, successful sealing and restoration of luminal patency is achieved in the 
range of 90-100%.16-22 For non-malignant esophageal leaks, these results are confirmed in our 
current series. The minimally invasive nature of expandable stents is appealing, but concerns 
are raised about the complications during SEMS treatment and SEMS removal.23-25 During 
SEMS therapy reintervention rates reportedly range from 35% to 40%, mainly due to migra-
tion of the device.19, 26-27 FcSEMS are more prone to migration than pcSEMS as the full covering 
prevents the metal wires from imbedding into the tissue. However, the downside of this is 
that tissue ingrowth increases the risk of stent removal.2, 28 
To date no randomized controlled trials have been published comparing partially versus fully 
covered SEMS for temporary use. In this series, a total of 22 fcSEMS and 22 pcSEMS were inserted 
in patients with benign esophageal perforations (n=32) and stenosis (n=12). A higher migration 
rate occurred in fcSEMS than in pcSEMS (36% versus 18%), however this was not statistically sig-
nificant. In an attempt to decrease the rate of stent migration, various modifications have been 
proposed, including the use of clips, silk threads connecting the stent to the patient’s earlobe, 
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and even pre-treatment with circumferential EMR of the middle of the esophagus for stricture 
formation, with ambiguous results.17, 29-31 These techniques were not applied in our series.
Ideally, complete closure of the defect and restoration of luminal patency is achieved in a 
single procedure. However SEMS removal is required within a limited time-interval, as pro-
longed stenting beyond a period of six weeks leads to an increased risk of complications.1, 4 
In the present series, after 4 weeks of stenting closure of the leak was achieved in 52%, half 
of the study population required additional therapy to allow complete closure. In 7 out of 12 
patients (58%) with refractory strictures, SEMS were removed within four weeks because of 
intolerance to SEMS therapy or SEMS migration. Only one (8%) patient was free of dysphagia 
one month after SEMS removal. In a recent published series from our institution, SEMS were 
placed in 33 patients with benign esophageal leaks. This led to healing in 70% of patients 
after a median duration of 6 weeks.1 Eloubeidi et al. reported recently their experience with 
fcSEMS in 16 patients with esophageal leaks and 19 patients with benign esophageal stric-
tures. SEMS were in position for a median interval of 58 days (range 6-300 days). The authors 
also reported higher rates of clinical success in patients with leaks than those with stenosis 
(44% vs 21% respectively).27 Another study reported outcomes in 30 patients treated with 84 
SEMS for benign esophageal strictures. The results in this study were disappointing as persis-
tent improvement after stent removal was only achieved in 5 of 30 patients (17%).32 Based on 
these results, the use of SEMS for refractory stenosis cannot be routinely recommended and 
should be limited to strict indications.
Despite the superiority of uncovered SEMS over their covered counterparts in prevent-
ing stent migration, they have their own limitations. Partially-covered devices have been 
associated with epithelial hyperplasia. Embedding the stent in the esophagus, making 
their removal particularly difficult. Tissue ingrowth is created by a local fibrotic reaction and 
proliferation of granulation tissue.33 This tissue reaction can be clinically manifest as early 
as 2 weeks after stent placement, but occurs more often after a longer time-interval.4, 34 In 
a recent published retrospective series of 110 SEMS removals in patients with benign and 
malignant esophageal disease, successful removal of both partially- and fully-covered SEMS 
was feasible at first attempt in the majority of cases. Prolonged stent therapy was associ-
ated with increased numbers of complications.4 Therefore in our series, SEMS were removed 
within 1 month post-SEMS insertion. Despite of this short time-interval, severe complications 
occurred during two (9%) pcSEMS removals. No complications occurred with fcSEMS (ns). 
The strengths of this study are the prospective randomized design and the robust short-
term follow-up after removal. This enabled us to assess both clinical outcomes as well as 
all the complications. However, this study has several limitations. First, the 2 types of SEMS 
used in this series were not only different in the extent of their covering, but also in an ar-
ray of characteristics including their expansible force, length of their flanges, and diameter. 
Therefore, not only covering, but also other factors may have attributed to the observed 
differences. Secondly, the clinical success rates reported are based on observations at the 
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time of stent removal and one-month after SEMS removal; long-term success rates cannot be 
determined. However, re-occurrence of benign esophageal leaks after closure, as opposed 
to re-stricturing of benign stenosis, is a rare event. Thirdly, this is a single center study per-
formed in a unit with an exceptionally high volume of SEMS placements and all stents in this 
study were placed and removed by an expert endoscopist (JH) in this field. 
In conclusion, this randomized controlled trial showed that both the partially-covered Ul-
traflex stent and the fully-covered Hanarostent are equally effective in sealing non-malignant 
esophageal fistulae and restoring luminal patency. A major drawback of these stents is the 
re-occurrence of dysphagia and leakage caused by SEMS migration, with no significant dif-
ference between the two stent types. SEMS in patients with refractory strictures were poorly 
tolerated and furthermore the short-term effects on the dysphagia score were dissatisfying. 
All SEMS were successfully removed at one month post SEMS insertion. However during 2 
pcSEMS removals severe complications occurred. Since removal of partially covered stents is 
considerably more complex than removal of fully covered stents, we advocate the use of fully 
covered expandable metal stents for this indication. Additional studies and modified stent 
designs are needed to further characterize which patients can benefit from these interven-
tions, and which type of stent is most suitable for temporary use.
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INTRODuCTION
Self-expanding metal stents (SEMS) have become a leading palliative therapy for dysphagia 
resulting from esophageal cancers. This device immediately restores luminal patency and 
thereby improves oral intake and quality of life. In recent years, the indications for covered 
metal stents have gradually expanded to a variety of benign esophageal conditions of the 
upper gastrointestinal tract. SEMS consist of woven, knitted, zig-zag or laser-cut metal mesh 
cylinders, which exert self-expandable radial force until they reach their maximum fixed 
diameter. They are generally made from a grid of stainless steel or nitinol and are covered 
with a polyethylene, polyurethane, or silicone layer. Placement of a SEMS in the esophagus 
is performed by appropriately trained endoscopists after comprehensive interdisciplinary 
collaboration with relevant specialty teams, including gastroenterologists, oncologists, and 
surgeons.
MAIN OuTCOMES
Stenting malignant esophageal disease 
By measures of mortality and morbidity, gastrointestinal (GI) cancers are dominating the field 
of oncology. Between one fifth and one quarter of all human cancers arise in the digestive 
system. Many patients with digestive cancer present with incurable disease. Advanced diag-
nostic and therapeutic tools have been developed to detect and treat cancerous lesions at 
the earliest stage. A review (chapter 2) focused on recent developments in prevention, detec-
tion and the approach to early gastrointestinal cancer. The incidence, diagnostic techniques, 
and therapeutic options have undergone major changes over the last six decades, but the 
prognosis generally remains poor. This in particular pertains to advanced stage disease, in 
spite of aggressive adjuvant therapy and advances in surgical resection techniques. As locally 
advanced cancer often goes with distant metastases, treatment options are mostly limited 
to systemic treatment or local palliation. Rapid and persistent palliation of dysphagia is the 
main challenge in patients with incurable esophageal cancer.
Brachytherapy and stent placement are the two evidence-based treatment options in these 
patients. Two randomized controlled trials comparing brachytherapy with stent-therapy 
showed that SEMS placement provides more rapid palliation of dysphagia as compared to 
brachytherapy.1-2 The difference in efficacy decreases gradually over time, and after 3 months 
brachytherapy seems to provide better palliation. However in the study of Homs et al. nearly 
half of the patients in the brachytherapy group received additional stent therapy, and only 
2% of the patients in the stent therapy group received additional brachytherapy.1 Therefore, 
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the positive long-term effects of brachytherapy can partly be explained by additional SEMS 
placement during follow-up, because of insufficient brachytherapy effect.
Even after curative surgery, the median esophageal cancer-specific survival is only 38 
months. The esophageal cancer-free survival rate at 1, 2, and 5 years is approximately 84%, 
65%, and 41%, respectively.3 Many of these patients present with recurrent dysphagia as a 
signal of recurrent disease.4-7 Although chemotherapy and radiotherapy can be effective for 
symptom relief for locoregional tumor recurrence, it can take as long as several weeks for 
such therapy to relieve dysphagia.1, 8 Given the short life expectancy in these patients, more 
rapid relief is usually required. We performed a prospective observational study evaluating 
SEMS therapy in patients with recurrent cancer after esophagectomy (chapter 3). In this 
series, we placed 100 SEMS in 81 consecutive patients with cancer recurrence. Respiratory fis-
tulae and esophageal stenosis were present in 19% and 81% respectively. Fistulae represent 
a devastating complication leading to recurrent pulmonary infections and the inability to 
eat or even swallow saliva. This condition is associated with very high short-term mortality.9 
The technical success of fistulae sealing and restoring luminal patency by SEMS placement 
was 93% versus 98% respectively.10 In the majority of patients with cancer recurrence after 
esophagectomy, the fistula or stenosis is located close to the upper esophageal sphincter. 
At this location, SEMS placement may cause foreign body sensation, trachea compression, 
or respiratory fistula.11-12 It has been hypothesized that stents should have a body diameter 
of 18 mm or less to avoid these complications.13 In our series, however, three patients (4%) 
developed a stridor and two patients (2%) developed a fistula after stent placement, despite 
the use of small diameter stents in four of them. None of the patients reported globus sensa-
tion. This study showed that SEMS placement in recurrent esophageal cancer after surgical 
resection offers adequate palliation. Stent dysfunction occurred in 30% of patients. They all 
were successfully managed by subsequent endoscopic intervention without complications.
Tumors causing extrinsic compression of the esophagus also may also be responsible for 
malignant dysphagia. In the majority of patients, dysphagia due to malignant extrinsic 
compression is caused by pulmonary carcinoma or by the recurrence of esophageal cancer 
after surgery.14-15 There is some evidence that better dysphagia relief can be obtained when 
uncovered stents are utilized for intrinsic obstruction than for extrinsic obstruction.14 To 
date, there are no published series evaluating covered SEMS for extrinsic malignant stenosis. 
We therefore performed a prospective observational study and included 50 consecutive 
patients with malignant extrinsic compression with an indication for stent therapy (chapter 
4). Placement was successful in all patients. Procedure related complications occurred in two 
patients (4%) during endoscopic dilation of a tight stenosis prior to stent insertion. These 
perforations were successfully sealed with the covered SEMS. Recurrent dysphagia occurred 
in 16% and was successfully managed by subsequent endoscopic intervention. In this series, 
the type of stent (partially- vs fully-covered) and radiation and/or chemotherapy prior to 
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stent placement, did not influence the clinical outcome. Survival after stent placement is 
obviously a function of the timing of stent insertion in relation to the disease stage. In our 
series, 96% of patients had grade 3-4 dysphagia on inclusion, and the median survival time 
in our series was only 44 days. In patients with extra-esophageal tumours, the tumour has 
to have spread and grown substantially in order to compromise the esophageal lumen. This 
may explain the relatively short survival period of these patients over that of patients with 
intrinsic esophageal tumours.16-17 
Endoscopic reinterventions are generally associated with patient burden, as well as signifi-
cant costs and risks, even when they are successful.18 A wide variety of expandable esopha-
geal endoprostheses have been developed to improve therapeutic outcome and to reduce 
the need for endoscopic reintervention during the course of the disease. To our knowledge, 
previous randomized controlled trials did not show any SEMS significantly superior in all 
aspects to other SEMS types.19-21 Currently, the Ultraflex® stent is worldwide most frequently 
used. The Evolution® stent has recently been introduced as an alternative with modified 
stent characteristics. To date no comparative studies have been published with the Evolu-
tion stent. One recent open-label study with this new device reported major complications 
in 8% and dysphagia recurrence in 25% at a median survival of 88 days.22 We performed a 
prospective randomized controlled trial in 80 patients with malignant esophageal disease, 
and compared the conventional Ultraflex stent with the new design Evolution stent (chapter 
5). This study showed that the Ultraflex stents and Evolution stents were equally effective in 
the relief of malignant dysphagia and sealing fistulae. The observed overall complication rate 
of 30% in our series was substantial, yet in the middle of the range in recent reports.7, 10, 23 In 
our series major complications arose more often after Ultraflex stent placement. The most 
common complication was hemorrhage, which -remarkably- only occurred in the Ultraflex 
stent group. Patients treated with an Ultraflex stent also needed significantly more reinter-
ventions than those treated with an Evolution stent. In the Ultraflex group, 38% of patients 
within 90 days required one or more interventions to manage stent dysfunction, which is 
in line with previous published series.18, 24-25 Yet, only 10% of patients in the Evolution group 
required re-intervention. This is low compared with the literature on malignant esophageal 
stenting. These results set the preference for the Evolution stent over the Ultraflex stent for 
patients with malignant esophageal disease. The observed benefits in the performance of 
the Evolution stent may likely be ascribed to the new stent design and resulting physical 
characteristics. These characteristics include the higher hoopstrength (radial force), silicone 
internal and external coatings to prevent ingrowth, large dual flanges to prevent migration, 
and a large stent diameter to avert food-bolus obstruction as compared to the Ultraflex stent.
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SEMS are generally used as palliative treatment for patients with a limited life expectancy, 
with no intention of subsequent stent removal.25 Side effects such as ulceration, stricture 
formation, perforation, and bleeding are well-known complications of long-term stent 
placement.26-30 To avoid these complications, timely removal of SEMS in patients with benign 
esophageal disease is crucial. Currently, partially- and fully-covered SEMS have been increas-
ingly used as a temporary device in patients with benign esophageal perforations or steno-
sis.7, 30-36 Stents are also successfully used as a bridge to therapy and to maintain oral intake 
before surgery or chemotherapy and radiotherapy.37-38 Some studies reported unacceptable 
rates of complications caused by temporary stent placement.39-42 The main problem associ-
ated with partially-covered SEMS placement in benign esophageal disorders is endoscopic 
stent removal. Partially-covered devices have been associated with epithelial hyperplasia, 
embedding the stent in the esophagus, making their removal particularly difficult. Tissue 
ingrowth is created by a local fibrotic reaction and proliferation of granulation tissue.43 This 
tissue reaction can be clinically manifest as early as 2 weeks after stent placement, but occurs 
more often after a longer time-interval.44-45 We performed a prospective observational study 
and assessed the feasibility of SEMS removal in a large cohort of patients with malignant 
and benign esophageal disease (chapter 6). A total of 124 esophageal SEMS removals were 
attempted in 95 patients at a single institution. The uncomplicated primary removal rate 
was 89%, which is lower than the 97 to 100% in previously published series.34, 46-47 However, 
this series comprised both fully- and partially covered SEMS, a variety of indications and 
dwell-time after insertion. After 1 to 7 endoscopic sessions, 96% of all stents were removed 
endoscopically; 3 stents (2.4%) were surgically removed and 2 stents (1.6%) were left in 
place. Successful endoscopic removal was time dependent; patients with an uncomplicated 
primary SEMS extraction had the stent significantly shorter in place as compared to patients 
with a complicated or failed SEMS extraction. These observations should caution clinicians to 
leave stents in for a prolonged period of time. 
Complications occurred in 6% of the SEMS removals. The most commonly encountered 
complication was stent breakage, which occurred as a result of endoscopic traction with the 
retrieval forceps in 5 of 124 removals (4%). Similar rates have been reported by other groups 
(0-5%).34, 46-50 Caution should be taken when using overlapping SEMS as a temporary device; 
2 patients with SEMS breakage had overlapping stents in place (p<0.05). In case of stent 
breakage and possibly incomplete endoscopic stent removal, careful endoscopic evaluation 
or surgery should be considered to ensure that all broken segments have been removed. 
Broken filaments may migrate and subsequently may lead to life-threatening complications 
such as perforation or empyema, which occurred in two patients years after SEMS removal. 
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Despite serious concerns regarding the long-term complications and hitches related to 
the stent-extraction, stent placement was in recent years the treatment of first choice for 
all patients with a benign esophageal perforation referred to our unit.39, 51 We performed a 
prospective series and studied the efficacy of short-term stent placement in 33 patients with 
non-malignant esophageal perforations (chapter 7). The proportion of perforations directly 
sealed after employment of a covered stent in malignant fistula is in the range of 90% to 
100%.52-54 In our series, 97% of the lesions was directly sealed after stent insertion. There are 
no accepted criteria with regard to the optimal duration of stent therapy. Ideally, a single 
stent seals the esophageal wall defect, permit normal food intake, allow the esophageal 
wall to heal, and be easy to extract, thereby minimizing the number of complications while 
preserving the esophagus. With regard to duration of stent therapy this poses conflicting 
demands. Previously published series reported controversial data on the optimal stenting 
period.30-31, 33, 40, 55-56 Most series recommend stent removal between 3 and 10 weeks.31, 33, 57 
However, Choi et al. reported successful stent removal even after 8 years.55
In our series, stents were retrieved endoscopically after a median of 5 weeks post-stent 
insertion. Complete closure of the defect was observed in 23 out of 33 patients (70%) at a 
median of 6 weeks after initial treatment. All stent extractions within 6 weeks after insertion 
were uneventful. Importantly, this study shows a considerable rate of serious complications in 
those cases in which stents were extracted after more than 6 weeks after stent insertion. Ten 
stents were in place for more than 6 weeks and all were firmly embedded into the esophageal 
mucosa. Extraction resulted in 6 major complications. Based on our results, we advocate re-
moving the SEMS within 6 weeks after placement in patients where stent removal is deemed 
necessary regardless of stent type. In case of persisting symptoms after stent removal, stent 
reinsertion is the preferred approach.30, 58
Overall therapeutic outcome depends both on successful sealing of the wall defect and the 
success of subsequent SEMS removal. As fully covered and partially covered SEMS differ 
in both respects, a comparative study was performed in our institution (Chapter 8). This 
randomized controlled trial included 44 patients with benign esophageal disease. A total of 
22 fully-covered Hanarostents® and 22 partially-covered Ultraflex® stents were inserted in pa-
tients with benign esophageal perforations (n=32) and stenosis (n=12). Both partially-covered 
Ultraflex stents and fully-covered Hanarostents were highly effective in sealing fistulae and 
restoring luminal patency. A major drawback was the re-occurrence of dysphagia and leak-
age caused by SEMS migration, with no significant difference between the two stent types. 
All SEMS were successfully removed at one month post SEMS-insertion, however during 2 
partially-covered SEMS removals severe complications occurred. After SEMS-removal closure 
of the leak was achieved in 52%, half of the study population required additional therapy to 
allow further mucosal healing. In 7 out of 12 patients (58%) with refractory strictures, SEMS 
were removed within four weeks because of SEMS intolerability and SEMS migration. Only 
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one (8%) patient was dysphagia free one month after SEMS removal. Eloubeidi et al. reported 
recently their experience with fully-covered SEMS in 16 patients with leaks/perforations and 
19 patients with benign esophageal strictures. SEMS were in position for a median interval 
of 58 days (range: 6-300 days). They also reported higher rates of clinical success in patients 
with leaks than for stenosis (44% versus 21% respectively).59 Holm et al. reported outcomes of 
84 stents in 30 patients with benign esophageal strictures. In only 5 of 83 interventions (6%), 
long-term improvement was achieved after stent removal.60 Based on these results, the use 
of stents for refractory strictures cannot be routinely recommended and should be limited to 
strict patient selection, until there is significant improvement in stent design. 
CONCluSIONS AND FuTuRE DIRECTIONS
Technology in the field of gastroenterology is developing at an exponential pace. Detection 
of precancerous lesions in moderate to high risk populations is an essential clinical goal. New 
optical and therapeutic developments are rapidly in progress. Despite the many enhance-
ments, overall progress in the outcome of esophageal cancer remains poor. The majority of 
patients with esophageal cancer have inoperable disease at presentation. In these patients 
palliative therapy is the only treatment option. This thesis showed that covered-expandable 
stents are highly useful in restoring luminal patency and sealing esophagorespiratory fistulae 
in patients with intrinsic and extrinsic lesions, and also in recurrent cancer after esophagecto-
my. Unfortunately, there are a number of shortcomings with the current stent designs. Short-
comings include chest pain, hemorrhage, stent migration, and the possibility of recurrent or 
unresolved dysphagia or leakage. With the modification of the conventional self-expandable 
metal stent, significant improvement in the therapeutic outcome has been achieved. With 
their potential for removability, stents can be effectively used for benign esophageal disease. 
Stenting have encouraged a shift away from conventional surgery, as they successfully seal 
perforations and allow mucosal wall healing. SEMS cannot be routinely recommended in the 
treatment of refractory benign esophageal strictures until there is significant improvement in 
the stent design as they are generally poorly tolerated and furthermore long-term outcomes 
are dissatisfied. The minimally invasive nature of expandable stents for benign esophageal 
disease is appealing, but serious complications during removal do occur. SEMS removal 
should be performed within a limited time-interval of less than 6 weeks, and furthermore 
overlapping stents should be avoided. 
Stent designs will continue to evolve. Fully absorbable stent designs, radioactive stents, 
and drug eluting stents, that cause no tissue reaction are of particular interest to prevent 
complications of stent removal and may play a future role in the management of recurrent 
benign conditions, including refractory strictures or achalasia. Expectations for future tech-
nology are high; however to establish the value of various advanced diagnostic and thera-
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peutic tools, long-term outcomes of randomized controlled trials are required. Furthermore, 
patients should be carefully selected and closely monitored. 
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The studies described in this thesis address the role of stent therapy in malignant and benign 
esophageal disease. Our set of studies summarized here, sheds new light on knowledge of 
the indications for esophageal stenting and the common drawbacks associated with differ-
ent stent designs. These studies allow physicians to select stents for a particular condition 
as well as to anticipate complications such as stent dysfunction and difficulties concerning 
stent removal.
Chapter 1 describes the aims and the outline of this thesis.
Chapter 2 provides an overview of recent developments in prevention, detection and the 
approach to early gastrointestinal cancer. In addition, future directions to improve  survival 
are discussed.
Chapter 3 and beyond then focus on the treatment of esophageal disease by means of self-
expandable metal stents (SEMS). Chapter 3 describes the value of SEMS therapy in patients 
with recurrent cancer after previous surgical esophagectomy. In this prospective observa-
tional study of 81 patients with recurrent cancer after previous surgical esophagectomy, 100 
esophageal SEMSs were inserted for dysphagia (n=66 patients) or fistula formation (n=15 
patients). SEMS therapy restored luminal patency in 65 (98%) of 66 patients and sealed 
malignant fistulae in 14 (93%) of 15 patients. Stent dysfunction occurred in 24 (30%) of 81 
patients. They all were successfully managed by subsequent endoscopic intervention. After 
stent placement, a total of 16 complications were observed. Major complications occurred 
in 9 (11%) of 81 patients, mild complications occurred in 7 (9%) of 81 patients. The overall 
30-day mortality rate after stent insertion was 25%. Progression of the disease resulted in 
death after a median interval of 70 days (range 1 day - 91 months). These results demonstrate 
that insertion of SEMS offers good palliation in patients with recurrent esophageal cancer, 
by relieving dysphagia and sealing off esophageal respiratory fistulae. Therefore, in these 
patients who have a limited life expectancy, SEMS placement should be considered the treat-
ment of choice.
Chapter 4 outlines the role of SEMS therapy in a large cohort of patients with malignant 
extrinsic compression of the esophagus. Between 1995 and 2009, 50 consecutive patients 
with malignant extrinsic compression who had undergone SEMS placement were included 
(94% male; mean age 64 years). In the majority of patients, extrinsic esophageal compression 
was caused by obstructive pulmonary cancer (n=23) and by mediastinal metastasis after 
esophagectomy for esophageal cancer (n=16). Stent placement was technically successful 
in all patients. Severe complications occurred in 5/50 patients (10%) including perforation 
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during dilation prior to stent insertion (n=2) and hemorrhage (n=3). Two patients (4%) died 
from bleeding. Mild complications were seen in 9/50 patients (18%). Recurrent dysphagia 
occurred in eight patients (16%) and was successfully managed by subsequent endoscopic 
intervention. Median survival after stent placement was 44 days (range 5 days - 2 years). 
The median stent patency of 46 days in this series exceeded median patient survival. These 
results demonstrate that insertion of a SEMS is an effective palliative treatment for patients 
with dysphagia due to malignant extrinsic compression. In spite of the short survival, some 
patients present with recurrent dysphagia, which can be managed effectively by endoscopic 
re-intervention.
Chapter 5 describes a randomized controlled multi-center study, comparing the conven-
tional Ultraflex® stent with the new Evolution® in 80 patients with malignant esophageal 
disease. Patients were followed by scheduled telephone calls at one and three months after 
SEMS insertion. A total of 80 patients (73% male; median age 67 years) were included. One 
patient refused follow-up. Technical success was 100% in both groups. Reintervention rate 
was 15/40 (38%) for the Ultraflex and 4/39 (10%) for the Evolution stent (p=0.004). Major 
complications including aspiration pneumonia and bleeding occurred more frequently in the 
Ultraflex group (10/40 (25%)) compared to the Evolution group (3/39 (8%)) (p=0.04). There 
was no difference in overall survival between the two groups. These results set the prefer-
ence for the Evolution stent over the Ultraflex stent for patients with malignant esophageal 
disease.
Chapter 6 assessed the feasibility of SEMS removal. A total of 124 stent extractions were 
undertaken in 95 patients; both partially covered (68%) and fully covered (32%) SEMSs were 
removed. Three patients had 2 overlapping SEMSs in place. Successful primary removal was 
achieved in 89%; the secondary removal rate was 96%. Uncomplicated primary removal rate 
was significantly higher for fully covered versus partially covered stents (P=0.035) and for 
single versus overlapping stents (P=0.033). Patients with a complicated stent removal had 
the stent in place significantly longer compared with patients with an uncomplicated pri-
mary stent removal (126 days vs 28 days; P=0.01). Surgical removal was required in 3 patients 
(2.4%). Six moderate and severe complications (5%) related to the endoscopic extraction 
occurred. This study showed that primary endoscopic removal of a SEMS is feasible in the 
majority of patients with benign and malignant esophageal disease. A longer stent dwell 
time and the use of partially covered SEMSs both impede removal. Moreover, overlapping 
SEMSs should be avoided for temporary use because stent disintegration and subsequent 
complications may occur.
Chapter 7 evaluates the value of self-expandable metal stents in patients with benign 
esophageal perforations. Thirty-three patients underwent SEMS placement. Complete clo-
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sure of the defect was observed in 70% at a median of 6 weeks after initial treatment. All stent 
extractions within 6 weeks after insertion were uneventful. Importantly, this study shows 
a considerable rate of serious complications in those cases in which stents were extracted 
after ≥ 6 weeks after stent insertion. In all, 10 stents were in place for ≥ 6 weeks (range: 6 – 84 
weeks) and all were firmly embedded into the esophageal mucosa. Extraction resulted in 
six major complications. These observations should caution clinicians to leave stents in for a 
prolonged period of time. Although preservation of the esophagus is secondary to survival, 
this study shows that the esophagus can be preserved in the majority of patients.
Chapter 8 describes a randomized controlled trial, comparing the partially-covered Ultraflex 
stent® with the fully-covered Hanarostent®. This study included 44 consecutive patients with 
benign esophageal disease. Both the partially-covered Ultraflex stent and fully-covered 
Hanarostent were equally effective in sealing non-malignant esophageal fistulae and restor-
ing luminal patency. A major drawback of these stents was the re-occurrence of dysphagia 
and leakage caused by SEMS migration, with no significant difference between the two stent 
types. SEMS in patients with refractory strictures were poorly tolerated and furthermore the 
short-term effects on the dysphagia score was dissatisfying. All SEMS were successfully re-
moved at one month post SEMS-insertion. However during 2 partially-covered SEMS remov-
als severe complications occurred. Since removal of partially covered stents is considerably 
more complex than removal of fully covered stents, we advocate the use of fully covered 
expandable metal stents for this indication.
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SAMENvATTINg
De hoofdstukken in dit proefschrift beschrijven de rol van stenttherapie bij patiënten met 
maligne en benigne slokdarmaandoeningen. De studies die hier in het kort worden samen-
gevat, werpen een nieuw licht op de indicaties en op de voor- en nadelen van het gebruik 
van verschillende typen stents. Deze resultaten bieden artsen de mogelijkheid om stents 
voor een specifieke aandoening te selecteren en eveneens om te anticiperen op stent gere-
lateerde complicaties.
Hoofdstuk 1 beschrijft de doelstellingen en de hoofdlijnen van dit proefschrift.
Hoofdstuk 2 geeft een overzicht weer van recente ontwikkelingen op het gebied van de 
preventie en de behandeling van patiënten met een vroeg stadium van gastrointestinale 
tumoren. 
Hoofdstuk 3 beschrijft de rol van zelf-ontplooibare metale stents (self-expandable metal 
stent (SEMS)) bij patiënten met een recidief slokdarmcarcinoom na een oesofagusresectie. 
In deze prospectieve observationele studie zijn 81 opeenvolgende patiënten geïncludeerd, 
waarbij in totaal 100 slokdarmstents zijn geplaatst. Bij 66 patiënten was een slokdarmstent 
geïndiceerd voor dysfagie op basis van een maligne slokdarmstenose, bij 15 patiënten was 
een stent geïndiceerd  voor een maligne slokdarmfistel. Het plaatsen van een SEMS resul-
teerde in een goede doorgankelijkheid van de oesofagus bij 65 (98%) van de 66 patiënten en 
dichtte maligne slokdarmfistels af bij 14 (93%) van de 15 patiënten. Stent dysfunctie trad op 
bij 24 (30%) van de 81 patiënten. Deze patiënten waren allen succesvol behandeld middels 
een endoscopische reïnterventie. In totaal ontstonden er 16 complicaties na het plaatsen van 
een stent. Ernstige complicaties traden op bij 9 (11%) van de 81 patiënten, milde complica-
ties traden op bij 7 (9%) van de 81 patiënten. De 30-dagen mortaliteit na stentplaatsing was 
25%. Progressie van de ziekte resulteerde in het overlijden van patiënten na een mediane 
duur van 70 dagen (variërend van 1 dag tot 91 maanden). Bovengenoemde resultaten tonen 
aan dat het plaatsen van een SEMS een effectieve behandeling biedt voor patiënten met een 
recidief maligniteit na een oesofagectomie. SEMS zijn effectief voor zowel het afdichten van 
slokdarmfistels alsmede voor het opheffen van stenosen. Bij deze patiënten met een zeer 
beperkte levensverwachting is het plaatsen van een SEMS de therapie van keuze.
Hoofdstuk 4 beschrijft de rol van SEMS therapie bij een groot cohort patiënten met dysfagie 
op basis van maligne extrinsieke compressie. Tussen 1995 en 2009 zijn er in totaal 50 pati-
enten geïncludeerd. Bij de meerderheid werd extrinsieke compressie veroorzaakt door een 
obstructief longcarcinoom (n=23) en door mediastinale metastasen na een oesofagectomie 
(n=16). Plaatsing van een stent was bij alle patiënten technisch succesvol. Ernstige complica-
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ties, waaronder bloedingen (n=3) en perforaties tijdens dilatatie voorafgaand aan het plaat-
sen van de stent (n=2), traden op bij 5/50 (10%) patiënten. Twee (4%) patiënten overleden 
ten gevolge van de bloeding. Milde complicaties traden op bij 9/50 (18%) patiënten. Recidief 
dysfagie ontstond bij 8 (16%) patiënten. Zij werden allen succesvol endoscopisch behandeld. 
De mediane overleving na de stentplaatsing was 44 dagen (variërend van 5 dagen - 2 jaar). 
In deze serie was de mediane doorgankelijkheid van de stent van 46 dagen langer dan de 
mediane patiënten overleving. Deze resultaten tonen aan dat het plaatsen van een SEMS een 
effectieve palliatieve behandeling is voor patiënten met dysfagie ten gevolge van maligne 
extrinsieke compressie. Bij  een aantal patiënten ontstaat er opnieuw dysfagie ondanks hun 
korte levensduur. De meeste patiënten kunnen effectief behandeld worden middels een 
endoscopische interventie. 
Hoofdstuk 5 omvat een multicenter gerandomiseerde studie, waar de conventionele Ul-
traflex® stent met de nieuwe Evolution® stent wordt vergeleken bij 80 patiënten met een 
maligniteit van de oesofagus. Eén en drie maanden na het inbrengen van een SEMS werden 
patiënten telefonisch geïnterviewd. In totaal werden er 80 patiënten geïncludeerd (73% 
man; mediane leeftijd 67 jaar), 1 patiënt weigerde follow-up. Stentplaatsing was technisch 
succesvol bij 100%. Het aantal reïnterventies bedroeg 15/40 (38%) voor de Ultraflex stent en 
4/39 (10%) voor de Evolution stent (p=0,004). Ernstige complicaties waaronder een aspiratie 
pneumonie en bloedingen traden vaker op bij patiënten met de Ultraflex (10/40 (25%)) dan 
bij patiënten met de Evolution stent (3/39 (8%)) (p=0,04). Er was geen significant verschil 
in de mediane overleving tussen beide groepen. Op basis van deze resultaten verdient het 
plaatsen van een Evolution stent de voorkeur boven het plaatsen van een Ultraflex stent bij 
patiënten met een oesofagus maligniteit.
Hoofdstuk 6 beschrijft de haalbaarheid van SEMS verwijdering bij patiënten met benigne en 
maligne oesofagus aandoeningen. In totaal werden 124 stents verwijderd bij 95 patiënten; 
68% was gedeeltelijk gecovered, 32% was volledig gecovered. Drie patiënten hadden twee 
overlappende stents in de oesofagus. Stentverwijdering was endoscopisch succesvol bij de 
eerste poging bij 89%. Bij herhaalde poging was stentverwijdering succesvol bij 96% van 
de patiënten. Ongecompliceerde primaire verwijdering was significant hoger bij patiënten 
met een volledig gecoverde stent dan bij patiënten met een gedeeltelijk gecoverde stent 
(P=0,035). Bovendien traden er significant meer complicaties op bij patiënten met een enkele 
stent dan bij patiënten met twee overlappende stents in de oesofagus (P=0,033). Patiënten 
met een gecompliceerde stentverwijdering hadden de stent significant langer in de oesofa-
gus in vergelijking tot patiënten met een ongecompliceerde stentverwijdering (126 dagen 
versus 28 dagen; P=0,01). Bij drie (2,4%) patiënten werd de stent chirurgisch verwijderd. Zes 
(5%) matig ernstige tot ernstige complicaties ontstonden er gedurende of na het verwijderen 
van de stent. Deze studie toont aan dat een primaire endoscopische verwijdering van een 
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SEMS bij de meeste patiënten met een benigne of maligne oesofagus fistel of stenose suc-
cesvol is. Echter, als een stent voor een lange periode in de slokdarm zit, of als er 2 overlap-
pende stents zich in de slokdarm bevinden, dan is het risico op het ontstaan van complicaties 
gedurende het verwijderen van deze stents aanzienlijk. 
Hoofdstuk 7 evalueert de rol van SEMS therapie bij patiënten met benigne oesofagus per-
foraties. Bij 33 patiënten met een benigne laesie werd een SEMS tijdelijk in de oesofagus 
geplaatst. Na het endoscopisch verwijderen van de stent was bij 70% van de patiënten de 
perforatie succesvol geheeld. Alle stentverwijdering binnen zes weken na plaatsing verliepen 
ongecompliceerd. Dit onderzoek toont aan dat ernstige complicaties optraden bij het verwij-
deren van stents na een stent duur van ≥ 6 weken. In totaal werden 10 stents verwijderd na 
een periode van ≥ 6 weken (variërend van 6 - 84 weken). Deze stents waren allen ernstig 
ingebed in de mucosa van de oesofagus. Stentverwijdering bij deze groep resulteerde bij 
6 patiënten tot ernstige complicaties. Deze observaties moeten clinici ervan behoeden om 
stents voor benigne indicaties voor een langere termijn dan 6 weken in de slokdarm te laten. 
Deze studie toont aan dat met behulp van stenttherapie de oesofagus behouden kan worden 
bij de meeste patiënten met een benigne oesofagus perforatie.
Hoofdstuk 8 beschrijft een gerandomiseerde trial waarin de gedeeltelijk gecoverde Ultraflex 
stent® met de volledig gecoverde Hanarostent® wordt vergeleken. In deze studie werden 44 
opeenvolgende patiënten met een benigne  slokdarmfistel of een benigne slokdarmstenose 
geïncludeerd. De partieel gecoverde Ultraflex stent en volledig gecoverde Hanarostent ble-
ken vergelijkbaar effectief te zijn bij het afdichten van benigne fistels en bij het herstellen 
van de luminale doorgankelijkheid. Een belangrijk nadeel van deze behandeling was het 
opnieuw optreden van dysfagie of lekkage veroorzaakt door SEMS migratie; echter zonder 
significant verschil tussen beide typen stents. SEMS bij patiënten met refractaire stricturen 
werden over het algemeen slecht verdragen en bovendien was de verbetering van dysfagie 
vaak teleurstellend. Beide typen SEMS werden 1 maand na plaatsing succesvol verwijderd. 
Echter tijdens het verwijderen van 2 partieel gecoverde SEMS traden ernstige complicaties 
op. Aangezien het verwijderen van gedeeltelijk gecoverde stents aanzienlijk complexer is 
dan het verwijderen van volledig gecoverde stents, pleiten wij voor het gebruik van volledig 
gecoverde expandabele stents voor bovengenoemde indicaties. 
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